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1. General introduction
1.1. Hypoxia as selection method for tumor cells survival
Tumor is a disease characterized by an uncontrolled proliferation of altered
cells and, in order to sustain this rapid proliferation, tumor cells require a large
amount of nutrient to synthesize macromolecules useful for cellular division. The
main  problem encounters  by cells  of  solid  tumors  during  their  growth  is  the
increased distance from blood vessel which causes a shortage of oxygen necessary
to the cellular respiration, the principal way with which cells  obtain energy as
ATP, and in this conditions there is also a decrease of the availability of nutrients
necessary for biomass synthesis (carbohydrates, lipids, proteins). The first phase
of the growth of a tumor mass is characterized by normoxic conditions, in which
tumor cells  have enough oxygen for their  needs; on the contrary,  when tumor
mass reaches a dimension > 1 cm3, hypoxia can occur due to the distance from
blood  vessel  and  to  the  high  oxygen  consumption  resulting  from  the  rapid
proliferation (Granchi  and Minutolo, 2012); therefore, in order to survive tumor
cells have to adapt themselves to this conditions. In brief, hypoxia leads to several
changes aimed to allow cells survival in the shortage of oxygen (figure 1).
In  1920’s,  Otto  Warburg  had  observed  that  a  common  characteristic  of
several tumor tissues is a switch of cellular metabolism from the mitochondrial
oxidative  phosphorylation-based  process  to  an  “aerobic  glycolysis”  with
Figure 1. The main effects of hypoxia on tumor cells.
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concomitant high production of lactate and acidification of the extracellular pH;
this change is called “Warburg effect”. During the last years several studies have
been done to understand the reasons why this metabolic change takes place but the
only certain conclusion is that tumor cells have a typical metabolism; in particular,
there  are  several  evidences  about  the  overexpression  of  specific  isoforms  of
enzymes involved in the glycolysis in these cells and recently these enzymes are
considered as potential targets of future therapies aim to counteract tumor cells
proliferation (Granchi and Minutolo, 2012).
Another  effect  induced  by  hypoxic  condition  is  the  increase  of  the
invasiveness of tumor cells resulting in the possibility that metastasis could take
place. Among the hypoxia-induced processes that could favor tumor invasiveness
there is angiogenesis which is a process consisting in the building of new blood
vessels from existing ones to increase the availability of oxygen and nutrients;
unfortunately  anigogenesis  that  is  induced  in  tumor  tissues  results  to  be  an
important  stage  of  the  metastatic  process:  in  fact,  the  built  vessels  are
characterized by an altered walls thus they lost their selective permeability. In the
light of this  fact, cancer cells can push one way’s through extracellular matrix
thanks to the activity of specific enzymes, passing in blood stream and, at least,
reaching other anatomical districts where they can continue to proliferate. Even in
this process, specific enzymes are found to be overexpressed and involved in the
promotion of cells migration; these enzymes offer an interesting targets whose
inhibition can control metastasis growth in invasive phenotypes of cancer (Leber
and Efferth, 2009).
During my thesis period, I attempt to synthesize some compounds that were
developed with the purpose to counteract hypoxia-induced modifications on cells
metabolism and tumor invasivenss. On the base of their effect, these compounds
can be divided into two main categories:
 substances interfering against tumor metabolism that consist of two groups
divided on the  basis  of  their  target:  one  class  of  compound  comprises
inhibitors  of  glucose  transport  while  the  second  group  of  compounds
include  two  structurally  different  substances  which  counteract  the
conversion of pyruvate into lactate;
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 a compound developed as potential inhibitor of metastasis progression that
interferes with the extracellular matrix re-modeling which is an important
step of cancer cells migration.
1.2. Hypoxia effects in tumor are mediated by HIF-1
The effects  induced by hypoxia in  the tumor mass are mediated by HIF
family, a group of transcription factors induced by hypoxic conditions.
HIF-1  is  a  basic-helix-loop-helix  protein  involved  in  cell’s  adaption  in
hypoxia condition. It is  made by two subunits,  HIF-1α and HIF-1β. HIF-1α is
sensitive to the oxygen level while HIF-1β is constitutively expressed. HIF-1α has
an oxygen-dependent degradation domain (ODDD) which is absent in HIF-1β; in
normoxic conditions, HIF-1α is also constitutively synthesized but it has a short
life because of mechanisms of control as post-translational modifications inced by
oxygen-dependet  enzymes  as  prolylhydroxylases  (PHD)  and  asparginyl
hydroxylase,  also known as factor inhibiting HIF-1 (FIH-1) (Figure 2).  PHDs
hydroxylate Pro402 and Pro564 located in the ODDD and in order to catalyze this
reaction they need of oxygen so these enzymes result active under normoxia. This
modification  promotes  the  conjugation  of  hydroxylated  HIF-1α  with  the  Von
Hippel-Landau  protein  (VHLp),  a  tumor  suppressor,  which  allows  poly-
ubiquitination and degradation of the HIF subunit (Masoud et Li, 2015).
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On the other hand, FIH-1 catalyzes the oxygen-dependent hydoxylation of
Asn803 of HIF-1 avoiding the interaction between the transcription factor and the
co-activator CBP/p300 which is necessary for the recognition of HRE of the genes
targets by HIF-1 (Masoud et Li, 2015).
When hypoxic condition occurs in a tumor mass, the lower level of oxygen
does  not  allow  the  catalysis  neither  PHDs  nor  FIH-1  and  the  resulting  non-
hydroxylated HIF-1α is stabilized so it migrates into the nucleus bounding HIF-1
β subunit with the subsequent activation of HIF-1 (Masoud and Li, 2015).
As represented in figure 3, HIF-1 binds DNA in corresponding to genes that
express the sequence 5'-RCGTG-3',  also known as hypoxia responsive element
(HRE),  thus  increasing the  encoding for  several  proteins  for  example  proteins
involved in the promotion of glycolytic flux as transporter of glucose as GLUT1
isoform, and specific isoforms of enzymes involved in the glucose metabolism as
the LDH-A subunit of lactate dehydrogenase resulting in the overexpression of
LDH5 isoform (Granchi and Minutolo, 2012).
Generally,  in  healthy  tissues,  the  proteins  encoded  by  HIF-1  allow  the
survival of cells in the presence of low oxygen level; in tumor tissues, the altered
activation  of  HIF-1  could  contribute  to  the  development  of  aggressive  tumor
phenotypes.  Moreover,  it  is  observed  that  the  activity  of  HIF-1  in  tumor  is
correlated with the overexpression of LOX, an enzyme normally responsible of
Figure 2. On the left, mechanism of regulation mediated by PHDs; on the right,
mechanism of regulation mediated by FIH.1
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the modeling of extracellular matrix but also involved in metastasis promotion as
seen in highly invasive tumors (Erler et al., 2006).
Figure 3. The effects of HIF-1 that are treated in this work
8
2. Effects of hypoxia in tumor tissues
2.1. Cellular metabolism in normal tissues
Glucose is the principal energy source of cells. In particular, healthy cells
have a metabolism principally aimed to maximize the production of energy for
their functions and for this reason in these type of cells, ATP is obtained through
cellular respiration, a process that produces a total of 36 molecule of ATP from 1
molecule of glucose.
Cellular  respiration  is  made  by  three  main  steps:  at  first,  glucose  is
transported inside cells through specific transporters and then it is subjected to
glycolysis,  a  series  of  reactions  that  converts  1  molecule  of  glucose  into  2
molecules of pyruvate; the glycolysis product is transported inside mitochondria
where it is oxidized by pyruvate dehydrogenase in acetyl-CoA which enters in
TCA cycle to be completely oxidized in CO2. During glycolysis and TCA cycle a
certain  amount  of  coenzymes  are  reduced;  in  order  to  re-start  the  metabolic
reactions,  the coenzymes  are  re-oxidized  through the  electrons  transport  chain
consisting in four multi-enzymatic complexes placed in the internal mitochondrial
membrane. These enzymatic complexes are able to oxidize the coenzymes and the
resulting electrons are finally transferred by the fourth complex to the oxygen
derived from lungs that is converted, together with 2H+, in water. During each
electrons  transport,  10  H+ are  transported  in  the  space  between  the  two
mitochondrial membranes and a proton gradient is created through the internal
one. This gradient is used by ATP synthese complex to synthesize ATP from ADP
and inorganic phosphate using the energy released from the transport  of  1 H+
according to their gradient, from outside to inside in the mitochondrial matrix, in
order  to  synthesize  1  ATP molecule.  Thus  electrons  transport  chain  and  ATP
synthesis are coupled in a process known as oxidative phosphorylation.
The resulting amount of ATP derives mainly from oxidative phophorylation
but even other ATP molecules are synthesized both by glycolysis and the TCA
cylce (Figure 4).
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In some cases as for example after an intensive physical effort, oxygen can
be  insufficient  to  complete  the  cellular  respiration  so  NADHproduced  by
glycolysis, process not susceptible to oxygen shortage, is accumulated without it
can  be  re-oxidized:  in  order  to  re-oxidize  the  coenzyme  (as  NADH)  in  this
condition, pyruvate derived from glycolysis is reduced to lactate through LDH, an
enzyme that needs of NADH to reduce pyruvate allowing the oxidation of this
coenzyme  into  NAD+.  The  entire  process  takes  name  of  lactic  fermentation.
Generally, the resulting lactate is finally transported in the liver where it is used
for anabolic reactions.
In conclusion, glycolysis is a process that can takes place both in aerobic
condition as a step of cellular respiration, and in anaerobic conditions allowing
energy support to assure cell survival (Figure 4).
2.2.  Tumor  mass  is  made  by  cells  differing  for  their
metabolism
Tumor cells, as such healthy proliferating cells, have specific requirements:
the purpose of the metabolism of differentiated healthy cells consist principally in
Figure 4. Glucose metabolism's simplified representation in
healthy cells. Red states for the aerobic pathway; blue states for
anaerobic pathway. Dashed arrows state the source of the oxidized
coenzymes. Bold arrows state for the source of ATP. (PD=
Pyruvate deyhdrogenase)
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the  optimization  of  ATP  yield  and  this  is  guaranteed  by  the  oxidative
phosphorylation while proliferating cells as tumor cells need to increase biomass
production necessary to mitosis maintaining the energy supply and to satisfy this
requirement several modifications take place on cellular metabolism (Heiden et al,
2009).
Although tumor cells  are  altered  proliferating  cells,  there  is  a  difference
between them because several factors can influence the metabolism of the former
cellular type resulting in the presence of different kind of cells in a tumor mass
that differs in their metabolism; on the contrary proliferating healthy cells undergo
to a rigorous control by growth factor (DeBernardis et al, 2008).
Indeed  in  a  tumor  mass  many type  of  cells  exist  which  differ  for  their
metabolism; in particular, the presence of these niches in the mass displays the
gradient of available oxygen and these niches can be distinguished also for the
lactate gradient produced by those cells characterized by aerobic glycolysis that is
more intense at higher distance from blood vessel (Dang et Semenza, 1999).
Generally, tumor cells in solid tumor can be divided into two main types:
cells proliferating in normoxic condition with a metabolism based on oxidative
phosphorylation  and  cells  living  under  hypoxic  condition  with  a  metabolism
shifted to the aerobic glycolysis; the latter cells are responsible of the high level of
lactate which causes a considerable decreasing of the extracellular pH (Dang and
Semenza, 1999).
Normoxic tumor cells are similar to proliferating healthy cells because both
proliferate in oxygen presence; the latter cells are subjected to a strong control of
growth  factor  (GF)  which  are  necessary  to  proliferation  stimulation,  on  the
contrary  the  former  seems  to  have  enhanced  an  insensibility  to  GF  stimuli
resulting in a constantly activated proliferation pathway.
In healthy proliferating cells, when growth factors binds specific receptors
placed  on  the  membrane,  several  transduction  signals  are  activated  and  these
signals influence the metabolic activity allowing changes aimed to sustain cellular
proliferation. A very important pathway activated by GF is PI3K/ Akt/ mTOR: the
bond of GF with specific receptors allows PI3K activation and the subsequent
phosphorylation of membrane phosphatidylinositle lipids which activate serine/
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threonine kinases as Akt and mTOR. The activation of these enzymes results in
increased uptake of nutrients, enhanced expression of specific genes regulating in
metabolic reactions and increased macromolecules biosynthesis; in particular, Akt
increases the rate of glycolysis and lactate production (Heiden  et al, 2009). As
showed  in  figure  5,  the  activation  of  PI3K  is  tightly  controlled  by  the
dephosphorylation  of  membrane’s  phosphatidylinositle  lipids  catalyzed  by
phosphatases as PTEN. Besides PI3K/ Akt/ mTOR pathway, some transcriptional
factors as Myc play an important role in cellular proliferation. Myc consist in a
family of  genes  as  c-myc  encoding  for  transcriptional  factors  involved in  the
control of glycolytic metabolism and in cellular proliferation; among them c-Myc
is a trascriptional factor that allows the encode of glycolytic enzymes and subunit
A of LDH; it also actives the biosynthesis ex novo of nucleotide aimed to genome
duplication and for this reason c-Myc is important into the enter of cells in S-
phase of cell cycle (Dang et Semenza, 1999). The result of all these mechanism
consists  in  the maximization of biomass production using the intermediates of
TCA cycle as bioprecursors in several pathways; gycolysis  rate is increased in
order to synthesize a higher amount of pyruvate which is consequently oxidized to
acetyl-CoA so  more  TCA  cycles  intermediates  are  obtained  to  be  used  as
precursor in several biosynthetic pathway. The main problem is glycolysis Vmax
which is higher than PDH activity so piruvate can accumulate in cells. In order to
avoid the inverse reaction, the excess of piruvate is reduced into lactate by LDH:
in this manner, inverse reactions are avoided and coenzymes are oxidized thus a
new cycle of metabolic reactions can start.  The TCA cycle’s intermediates are
used to biosynthesis thus, apparently, their concentration seem to can not satisfy
the  for  cellular  respiration;  this  shortage  is  compensated  by glutaminolysis,  a
pathway that converts glutamine in different intermediates of Krebs cycle with the
purpose to sustain cellular respiration rate (Figure 5)(Heiden et al, 2009).
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In  tumor  cells,  the  mutations  of  oncogenes  can  induce  an  insufficient
capability to regular cellular proliferation resulting in the continue activation of
proliferation stimulating pathway as PI3K/ Akt/ mTOR pathways independently
by  extracellular  signals.  In  tumor  cells  several  mechanisms  can  increase  the
activity of this pathway: for example, an elimination of the inhibitory activity of
PTEN  on  PI3K  is  possible  such  as  an  increased  expression  of  Akt  with
subsequently uncontrolled increased glycolytic rate (Heiden et al, 2009).
Figure 5. Metabolic pathways in proliferating cells (on top, Heiden et al., 2009) and the
pathways involved in their control. (on bottom, DeBernardis et al, 2008).
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2.3. Influences of hypoxia on cellular metabolism
Generally in proliferating cells the metabolic activity is conspicuous; when
hypoxic condition occurs, an adaption on this condition is necessary to allow cells
survival and proliferation.
HIF-1 is a transcriptional factor that is activated by hypoxia: in particular, as
previous seen,  HIF-1 allows the encoding of transporters that increase glucose
uptake and of enzymes that sustain the high rate of glycolysis producing lactate as
showed by the increased expression of LDH in this condition (Figure 5).
The metabolic switch is also allowed by the HIF-1-induced overexpression
of pyruvate dehydrogenases kinase (PDK) which inhibits pyruvate dehydrogenase
through phosphorylation avoiding oxidation of pyruvate in acetyl-CoA and the
subsequent introduction in TCA cycle: in this way, cellular respiration pathway is
blocked because of the insufficient oxygen level for electrons transport chain and
the necessary to avoid possible damages caused by mitochondrial produced ROS.
In normal tissues, HIF is activated only in hypoxic condition; surprisingly,
in tumor cells this metabolic shift can takes place in oxygen presence (Warburg
effect).  Initially  Otto  Warburg  has  hypothesized  that  this  switch  takes  place
perhaps to  compensate  an impairment  of oxidative phosphorylation due to  the
insufficient  oxygen;  this  possibility  is  ruling  out  when it  is  observed that  the
metabolic  switch  can  occurs  even  in  oxygen  presence.  At  first  sight  this  can
results to be disadvantage for cells to survive because the lower ATP yield in this
condition versus the oxidative phosphorylation yield, so several hypotheses have
been done to understand the reasons why this phenomenon happens. Among the
possible  causes  there  is  a  dysfunction  in  mitochondrial  DNA:  although  many
mitochondrial  mutations  effects  are  unknown,  it  is  seen  that  some  of  these
mutations can produce altered proteins involved in the oxidative phosphorylation
that can not guarantee the completion of the process and in this way they can
contribute  to  tumorigenesis.  Another  important  hypothesis  about  the  aerobic
glycolysis prevalence in tumor cells can derive from the alteration in the control
of  HIF expression:  as  previous  seen,  in  normoxic  conditions  PHDs allow the
recognition  of  HIF-1  from  VHLp  and  the  subsequent  degradation  of  the
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transcriptional factor in oxygen presence. For example,  a mutation in the gene
encoding for VHLp can produce an altered protein resulting in a stabilization of
HIF-1 in normoxia. The stabilization of HIF-1 in normoxic conditions occurs, for
example,  when  succinate  dehydrogenase  or  fumarate  hydratase  results  to  be
altered: in fact, PHDs require ketoglutarate and oxygen as substrates to produce
succinate;  when  enzymes  involved  in  the  catabolism  or  in  the  synthesis  of
succinate are mutated, an excessive succinate can be produced and it can inhibits
PHDs resulting in the stabilization of HIF-1 (Kim et al., 2005).
Another way in which HIF-1 results stabilized under normoxia consists in
alterations  resulting  in  a  nonfunctional  tumor  suppressor  p53 or  in  a  constant
activated PI3K/Akt/mTOR pathway that leads to the overexpression of HIF-1α.
On the other hand, alterations relative to Akt and Myc activity can result in an
increased aerobic glcolysis  rate  under  normoxia because the former can allow
GLUT and hexokinase encoding while the latter can induce the overexpression of
LDH-A subunit (Figure 6) (Kroemer and Pouyssegur., 2008).
These  are  only  some  of  the  various  hypotheses  about  the  origin  of  the
Warburg effect but it is still unclear if the metabolic switch is an adaptive response
to hypoxia or if an oncogenic activation of the aerobic glycolysis exists but it is
certain that cancer cells have an own metabolism that differs from normal cells.
Figure 6. Alteration that can result in cancer metabolic
reprogramming. Pink states for the activation of oncogenic
factors; green states for the loss of oncosuppressor. (Kroemer
and Pouyssegur, 2008).
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2.4. Advantages of the aerobic glycolysis
Although from aerobic glycolysis only 2 ATP are produced from 1 molecule
of glucose versus the 36 ATP resulting from oxidative phosphorylation, there are
many advantages for hypoxic tumor cells derive from this metabolic switch.
First,  aerobic  glycolysis  is  characterized  by a  higher  rate  than  oxidative
phosphorylation so the former way can satisfy the proliferation rate of tumor cells
allowing use of gycolysis intermediates as bio-precursors in several pathway, for
example  glucose  is  used  to  obtain  ribose  5-phosphate  while  dihydroxyacetone
phosphate  is  used  for  phospholipid  synthesis  and  pyruvate  is  used  to  obtain
alanine.  Second,  this  metabolic  pathway  promotes  cells  independence  from
oxygen so they can continue to proliferate even when hypoxia occurs. Third, HIF-
1 allows PDH expression thus the inhibition of the oxidative phopsphorylation
with  the  subsequent  blockage  of  oxygen  consumption  in  cells  avoiding  the
production of cytotoxic ROS in mitochondria.  Fourth,  hypoxic tumor cells are
characterized by chemo- and radio-resistance: thanks to the Warburg effect, these
cells  can  survive  far  from  blood  vessels  so  they  are  difficultly  reached  by
antitumoral drugs whereas the survival in hypoxia is the reason of the resistance
against ROS produced by γ-rays used in radiotherapy (Kroemer and Pouyssegur.,
2008).
The principal waste of these cells is lactate: it could decreases intracellular
pH leading to cells death and for this reason it is transported outside cells through
specific  monocarboxylated  transporter  (MCTs)  causing  the  characteristic
acidification of the extracellular pH common to several tumors and increased in
hypoxic regions  of tumor masses due to higher rate  of aerobic glycolysis  that
characterized hypoxic tumor cells. Lactate is not only a waste of cells metabolism,
in fact it contributes to radioresistance because it can inhibits the cytotoxicity of
ROS thanks to its antioxidant properties (Granchi and Minutolo, 2012).
Moreover,  there is  a  kind  of  “symbiosis” between normoxic  tumor  cells
which metabolizes glucose through oxidative phosphorylation and hypoxic tumor
cells: this mechanism is based on the normoxic cells use of lactate produced by
hypoxic  tumor  cells.  In  particular,  hypoxic  tumor  cells  reduce  pyruvate  into
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lactate  through  LDH5 and  the  product  is  expelled  outside  cells  with  MCT4;
MCT1 is the isoform that allows transport of extracellular lactate inside normoxic
tumor  cells  which the oxidize  the  intercepted lactate  through LDH1 to  obtain
pyruvate for their metabolism. In this way, the consumption of the bio-precursor is
optimized (Figure 7) (Granchi and Minutolo, 2012).
2.5. Hypoxia role in angiogenesis
Metastasis is a process made by several steps in which cancer cells leave the
primary  mass  thus  invading  surrounding  space  through  the  degradation  of
extracellular matrix (ECM) thanks to secreted proteases; then cancer cells reach
the blood vessels to infiltrate in the blood stream where they have to survive under
the  hostile  conditions  as  for  example  the  high  oxygen  concentration  and
lymphocytes presence: the crossing of blood consists in a selection against which
only  cancer  cells  particularly  resistance  and  aggressive  can  survive.  Then,
survived cells  can leave the capillaries  penetrating in  a new district  to form a
secondary mass. The increased interest about metastasis is explained by the fact
that a higher percentage of tumor patients death is correlated to the presence of
secondary masses (Leber and Efferth, 2009).
Figure 7. Lactate exchange between hypoxic tumor cell and normoxic
tumor cell (Granchi and Minutolo, 2012)
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At the basis of cancer cells migration and invasiveness there are alterations
in  different  mechanisms  as  growth  factor  signaling,  cell-cell  adhesion,  gene
expression and cellular motility.
Although cancer cells can invade other anatomical districts by direct way
through blood vessels or by an indirect way through lymphatic vessels, the former
is the main way. Considering this fact, angiogenesis represents a process that can
afford  cells  migration  from  a  tumor  mass  because  resulting  capillaries  show
important differences if compared to vessels of normal tissues: the structure of
tumor’s neo-formed vessels appears more chaotic, often enlarged, with a slower
blood  stream  and  in  some  cases  holes  can  be  present  in  the  wall  causing
hemorrhage. The structure of these vessels offers a way to cancer cells to reach
blood flow; the  main  obstacle  to  cellular  migration  is  the extracellular  matrix
(Leber and Efferth, 2009).
To  explain  angiogenesis  effect,  we  have  to  consider  that  when  a  tumor
grows,  it  reaches  the  avascular  phase  in  which  cells  continue  to  proliferate
exponentially: in this case, a balance between pro- and anti-angiogenic factors is
established and it can enhance the transition in the vascular phase if the former
factors prevail. Among pro-angiogenic factors there are all those proteins whose
expression is increased by Ras as VEGF, FGF and EGF; hence, in tumor tissues,
angiogenesis  can  be  promoted  by  mutated  oncogenes  that  can  reduce  the
expression of angiostatin and thrombospondin which are anti-angiogenic factors
or even by mutated oncosuppressors as for example the possible increased VEGF
expression due mutated p53. In this context, hypoxia plays an important role: in
fact,  HIF-1  also  allows  encoding  of  growth factors  as  VEGF involved in  the
formation of new blood vessels for existing ones (Leber and Efferth, 2009).
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3. GLUT1 as target in the treatment of tumor disease
3.1. Characteristics of GLUTs
Glucose is  the main source of cellular energy;  its  adsorption inside cells
requires  specific  transporters  and  among  them,  the  most  important  transport
belong to the GLUTs family.  The substrates of GLUTs are  D-stereoisomers  of
pentoses and hexoses specifically present as pyranosides although some of these
transporters can recognize principally fructose presents as furanoside (Deng et al,
2014).
The type of transport is an uniporter so it transports glucose in the direction
of  the  gradient.  The  proposed  transport  mechanism consists  in  the  alternative
accessibility of the substrate binding site in either side of the membrane due to
changing in the conformation of the proteins (Figure 9) (Deng et al., 2014).
GLUTs are transmembrane proteins that allow the transport of glucose and
other hexoses inside cells, in particular, the transport of glucose is the first rate-
limiting step of glycolytic metabolism. Until now, thirteen members are identified
and all members are classified into three class on the base of structural differences
(Figure 8). Class I includes GLUT1, GLUT2, GLUT3 and GLUT4; class II which
has  an  high  transport  activity  for  fructose  and  it  is  constituted  by  GLUT5,
GLUT7, GLUT9 and GLUT11 and, finally, class III comprises GLUT6, GLUT8,
GLUT10, GLUT12 and HMIT, an H+/myoinositole transporter (Macheda  et al,
2005).
From a structural point of view, GLUTs consist in a sequence of 400-600
aminoacids characterized by 12 transmembrane α helical domains with the C- and
N- termini of the chain located in the cytoplasmic side of the membrane. The
twelve  transmembrane  segments  (TMS)  are  organized  in  two  main  domains
identified as amino-  and carboxy- terminal  domains.  In each domains,  the six
TMS are divided in a couple where each element of the couple is made by 3 TMS;
3 TMS made one structural and functional unit. The N- and C- domains hide the
cavity  that  can  be  opened  towards  the  intracellular  space;  these  domains  are
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connected by an intracellular helical bundle (ICH) consisting in four α helices
which ensures the close of the intracellular gap when the extracellular gate of
GLUT1 is opened (Deng et al, 2014).
TMS sequences appear to be more conserved in all the members while loops
and terminals sequences are more variable; among the loops, loops 1 and 9 are the
most  variable.  Through  the  comparison  with  the  sequences  of  the  different
isoforms, it results that specific sequences in TMS and loops are constant due to
their importance in the bond with the substrate.
Figure 8. structure of GLUTs classes (Macheda et al., 2005)
Figure 9. Model of GLUT1 mechanism of transport (Deng et al., 2014)
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Another common characteristic is the presence of a large intracellular loop
located between TM6 and TM7. The differences among the GLUTs classes are
relative  to  the  localization  of  an  extracellular  loop  that  contain  an  N-linked
glycosylation site: in class I and II the described loop is placed between TM1 and
TM2 whereas it is located between TM9 and TM10 in class III.
Eight  of  the  twelve  TMS  have  amphipatic  properties  suggesting  an
interaction with the extracellular water and consequently with the extracellular
glucose.  Each  domain  comprises  six  TMS  and  two  TMS  of  each  group  are
hydrophobic (3 and 6 in N-terminal domain and 9 and 12 in C-terminal) which
anchor the other amphipatic TMS (Carruthers et al, 2009).
Other differences among the single members of each class consists in the
affinity for hexoses: for example, GLUT1, GLUT3 and GLUT4 have high affinity
for glucose whereas GLUT5 has higher affinity for fructose than glucose.
GLUTs isoforms characteristics are resumed in table 1.
It is thought that in the substrate binding site there is a specific sequence
responsible of the affinity for a specific hexoses.
Table 1. Characteristics of GLUTs (Zhao and Keating, 2009)
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3.2. GLUT1 overexpression in cancer cells
Different GLUTs have been found in several types of cancer, many of them
associated with aggressive phenotypes. This observation is according to the high
concentration of glucose necessary for the requirements of cancer cells: in fact,
the  expression  of  these  proteins  result  to  be  10-12  folds  higher  than  normal
tissues. PET studies done with 2-deoxy-2-(18F)fluoro-D-glucose (FDG), a labeled
glucose analogue,  show that  this  derivative results  to  be more accumulated in
cancer  cells  than  in  healthy  cells  thus  suggesting  an  increased  uptake  in  this
altered tissues. This observation is in accord to the fact that glucose is used not
only for energy but it is also necessary for anabolic reactions too; in particular,
glucose is the main starter to pentose synthesis pathway necessary for nucleotide
synthesis  which  is  especially  activated  in  several  tumor  cell  lines  than  in  the
corresponding normal tissues (Macheda et al, 2005).
Several studies have associated the overexpression of GLUT1 isoform to the
increased invasiveness potential of cancer and to a decreased survival of patients;
these results are sustained by the observation that PET scan intensity is higher in
high-grade tumor.
Moreover, mutations of  ras and sac oncogenes increase the expressions of
GLUT1 and GLUT3; the effect could be due to a direct genes mutations thus
resulting  in  the  deregulation  in  controlling  expression  of  genes  encoding  for
GLUT or also to an indirect effect due to the decreased intracellular concentration
of glucose because of its high consumption by cells (Macheda et al, 2005).
Different factors can regulated the expression of this transporter in cancer as
growth factors, hormones and especially hypoxia: in particular, HIF-1α is shows
to bind the GLUT1 promoter which contains the hypoxia response element thus
increasing the encoding of the transporter.
3.3. Interaction between GLUT and D-glucose
The crystal  structure of human GLUT1 isoform has been identified only
recently  from  studies  made  on  erythrocytes  where  this  isoform  is  mainly
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expressed allowing the constant supply of glucose. The first model obtained of
GLUT1  derives  from  X-ray  experiment  done  on  the  proton-coupled  xylose
transport XylE, Escherichia Coli which is a homologue of GLUT1 and GLUT4.
The interactions between the transporter and its substrate have been studies
analyzing  the  complex  between  XylE  and  D-glucose  through  X-ray
crystallography:  it  is  shown  that  the  hexose  is  trapped  in  the  center  of  the
transmembrane domains and each hydroxyl group is specifically recognized. In
particular  glucose  OH  groups  are  involved  in  hydrogen  bonds  with  the
aminoacidic  residues  Gln168,  Gln175,  Gln288,  Gln289,  Asn294,  Trp392  and
Gln415. Lipophilic interactions have been recognized due to the aminoacids that
delimit the binding site of the substrate with the residue as Phe24, Ile171, Ile287,
Ile293, Leu297, Tyr298 and Phe383. Successive analysis have demonstrated that
the interactions between the glucose and XylE are also conserved with hGLUT1,
with the only exceptions  of the interactions with Gln175, Leu297 and Gln415
(Tuccinardi et al., 2013).
3.4. GLUT1 inhibitors: background
Several evidences confirm the overexpression of GLUT1 in cancer cells and
different efforts are done to identify a selective inhibitors of this transporter; for
this  reason different  categories  of  compounds have been investigated for their
inhibitory activity on this protein (Salas et al., 2013).
The natural phytoalexin resveratrol  1 (figure 10) shows a large range of
biological  effects  and among  its  activities  there  is  the  capability  to  affect  the
glucose metabolism. Although its exact mechanism of action remains unclear, it
results  structurally  similar  to  molecules  able  to  inhibit  GLUT1  so  it  is
hypothesized that also resveratrol could interfere with this transporter.
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In  particular,  it  is  observed  that  resveratrol  acts  as  a  non-competitive
inhibitor of GLUT1 binding a specific site accessible from the internal surface of
the  transporter  and  therefore  it  does  not  allow  the  entrance  of  extracellular
glucose.(Salas et al., 2013).
Phloretin 2 (figure 11) is a dihdrochalcone found in apple tree leaves which
act  as  a  competitive  inhibitor  of  GLUT1.  It  shows an  ability  to  retard  tumor
growth  in  vitro and  in  vivo.  Moreover,  it  results  able  to  sensitize cancer  cells
towards  chemotherapeutic  agents  as  daunorubicin  in  colon  cancer  and  renal
carcinoma cells in hypoxic conditions (Granchi and Minutolo, 2012).
 Studies  about  its  activity  towards  GLUT1  was  enhanced  after  the
observation  that  phlorizin  (phloretin-2-glucoside)  caused glycosuria  due to  the
inhibition  of  glucose  re-absorption  in  kidney.  Phloretin  results  able  to  block
mainly the glucose efflux from erythrocytes than its influx, phenomenon named
“asymmetry of inhibition” (Martin et al, 2003).
On the basis of phloretin inhibition results and of its active configuration,
several flavonoids with different number of hydroxyl groups have been tested,
most  of  all  characterized  by  the  presence  of  a  cromane  ring  and  by  a  rigid
conformation. They result active in a pH-dependent manner and it is shown that
the absence of hydroxide groups leads to the inactivity (Martin et al, 2003).
Among the tested flavonoids there are compound which show an inhibitory
activity mainly towards other isoform of GLUT as GLUT2 (for example quercetin
3) and GLUT4 (for example naringenin 4) (figure 11) (Martin et al, 2003).
Other  flavonoids  with  inhibitory  activity  towards  GLUT1  have  been
identified. Sylibin, or silibinin, 5 (figure 11) is a flavonoid derived from Sylibum
marianum.  This  compounds is  investigated  for  its  activity towards  a  series  of
Figure 10. Resveratrol
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hepatic diseases and more recently for its antiproliferative acitvity towards cancer
cells; in addition, also the  6 derivative 2,3-dehydrosilybin (figure 11) has been
tested. Both the compounds show the capability to strongly inhibit the glucose
transport  mediated  by  GLUT4  as  observed  form  tests  on  insulino-stimulated
glucose uptake in adipocytes, where GLUT4 is the isoform induced by insulin,
and their  cytotoxicity seems to  be  related  to  GLUT4 expression  on plasmatic
membrane; in particular, compound 6 shows a lower Ki than 5. In addiction, these
compounds  have  been  tested  as  inhibitors  towards  other  isoforms  of  GLUT
resulting in a good activity towards GLUT1 although lower than GLUT4 (Zhan et
al, 2011).
 In particular, silybin shows to directly interact with GLUT1 and GLUT4
with a Ki = 60 μM leading to a strong inhibitory effect on growth and proliferation
of cancer cells (Granchi and Minutolo, 2012).
The synthetic compound WZB117 7 (figure 11) derives from poliphenolic
esters developed as GLUT inhibitors.  (Granchi  and Minutolo,  2015).  WZB117
shows to inhibits irreversibly the glucose uptake in a dose-dipendent manner. It is
observed that the inhibition degree is higher in hypoxia condition than normoxia.
Among GLUTs family, GLUT1 results to be WBZ117’s target (Liu et al, 2012).
This molecule has effects principally on human non-small lung cancer H1299 and
A594 cells lines than in human non-tumorigenic NL20.
On the  basis  of  the  structure  of  the  compounds  inhibiting  GLUT1,  it  is
attempts to investigate about the effects of steroideal compounds towards glucose
uptake: for example, desoxycorticosterone and its glucose-conjugate have shown
a  Ki  value  higher  that  phloretin.  Also  the  non-steroideal  antiestrogens
diethylstilbestrol 8 (Figure 11) and tamoxifen show an inhibitory activity towards
GLUT1 although with a Ki values higher than phloretin. In the light of the fact
that  phloretin  has  also  an  estrogenic  activity,  it  is  hypothesized  that  both  the
estrogen  activity  and  GLUT inhibition  are  two  common  properties  of  many
flavonoids. Several compounds have been tested on MCF7 cells culture showing a
considerable  activity.  Regarding  the  compounds  active  towards  estrogenic
receptors, they also share the structural planarity as well as shown in flavonoids
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derivatives. On the contrary of flavonoids derivative, they do not show inhibitory
activity in a pH-dipendent manner (Martin et al, 2003).
3.5. Introduction to the experimental section
Bearing in mind that some molecules developed as inhibitors of estrogen
receptors  as  for  example  tamoxifen  share  also  an  inhibitory  activity  towards
GLUT1 such as some poliphenolic compounds active on GLUT1 demonstrate an
estrogenic activity (Martin et al, 2003), the research team of the Univeristy of Pisa
had  investigated  about  the  possibility  that  some  oximic  derivatives  initially
developed by them as ERβ inhibitors could be active towards GLUT1. The effort
in  this  research  had been encouraged by the  observation  of  the presence of  a
common pharmacophoric elements also with the synthetic poliphenols series of
WZB117, compounds with higher activity towards this transporter especially in
hypoxic condition (Tuccinardi et al, 2013).
These  compounds  consisted  mainly  in  salicylaldoximes  and
salicylketoximes derivatives are shown in figure 12.
Figure 11. Compounds with inhibitory activity towards GLUT1
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Among  these  series  of  compounds,  both  salicylaldoximies  and  5-aryl-
substituted salicylketoximes had been developed as non-steroidal ERβ inhibitors
(Minutolo et al, 2001); in particular, between these two classes the latter resulted
more selective towards the target (Paterni et al, 2015) while the 4-aryl-substituted
salicyketoximes did not show appreciated affinity towards ER (Minutolo  et al.,
2009) so this last group of compounds theoretically might not cause important
side effects due to a possible interaction with ER (Granchi et al, 2015).
Among the families of compounds that had been tested, 4-aryl-substituted
salicyketoximes had been chosen for their relative inactivity towards ER; on the
contrary only some salicylaldoxime derivatives shared a more selective activity
towards GLUT than ER. For these reasons, the affinity of the 4-aryl-substituted
salicylketoximes  for  GLUT1 was evaluated  with  the  introduction  of  variously
substituted aryl rings in 4 position (Granchi et al, 2015).
Figure 12. Classes of oximic derivatives tested to evaluate their inhibitory activity
towards GLUT1
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Among  the  4-aryl-substituted  salicylketoximic  derivatives  (Figure  13),
compounds  9a,  9b,  9e,  9f,  9o had  shown  the  highest  inhibition  at  30  μM
concentration  in  percentage  terms  so  they  had  been  studies  at  various
concentrations to obtain a dose-response curves useful in order to determine their
IC50 values compared with phloretin and WZB117. Table 2 reports the values of
the most active compounds of the series.
Figure 13. 4-aryl-substituted salicylketoximic derivatives
synthesized to evaluate their activity towards GLUT1
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Compound GLUT1 assay in
H1299
H1299 cell growth ER RBA [%]
Glucose
uptake at
30 μM
[%]
Inhibition
IC50 [μM]
Viability
at 30 μM
[%]
Cytotoxicit
y IC50 [μM]
ERα ERβ
Phloretin 21 ± 9 21.4 ± 5.1 72 ± 10 54.0 ± 14.6 0.206 -
WZB117 16 ± 4 10.9 ± 3.6 35 ± 9 20.4 ± 4.8 - -
9a 9 ± 4 10.6 ± 2.8 42 ± 5 34.8 ± 5.8 0.0.12 ±
0.004
0.123
±0.030
9b 17 ± 3 15.5 ± 3.8 32 ± 4 39.6 ± 11.8 <0.001 0.002 ±
0.001
9e 16 ± 1 15.7 ± 2.0 22 ± 8 17.8 ± 2.8 <0.001 0.003 ±
0.001
9f 9 ± 3 7.0 ± 2.0 80 ± 8 45.8 ± 7.4 0.008 ±
0.002
0.010 ±
0.002
9o 8 ± 1 11.1 ± 2.6 62 ± 8 30.3 ± 5.9 0.018 ±
0.004
0.034 ±
0.004
Table 2. Inhibitory activities on glucose uptake and cell growth and ER relative
binding affinity values of compounds 9a, b, e, f, o. (Granchi et al., 2015)
In terms of SAR, the results suggested that the shift of the hydroxyl group
from para (9a) to meta position (9e) and the introduction of meta chloro (9f) and
meta methyl (9o) substituent to the hydroxyl group of compound 9a gave the most
active compounds. On the contrary, the replacement of  para OH of  9a with F,
CF3, OCF3, OCH3 and CN caused a drop of the activity such as the replacement of
meta OH of 9e with OCF3, OCH3 or CN (Granchi et al, 2015).
In order to determine eventual activity on ER, compounds 9a, 9b, 9e, 9f, 9o
underwent  to  a  radiometric  competitive  assay to  establish the  relative  binding
affinity  towards  ER.  It  has  been  demonstrated  that  9a and  9b have  a  certain
activity  on  ERβ comparing  to  phloretin’s  value;  on  the  contrary,  9e,  9f,  9o
derivatives  show a  negligible  activity  towards  these  receptors  (Granchi  et  al.,
2015).
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3.6.  Synthesis  of  the  4-aryl-substituted  salicylketoximic
derivatives
Figure 14 represents the general structure of the GLUT1 active compounds.
In this structure there are two aromatic rings B and C and a six-member pseudo-
ring  A resulting  from  the  H-bond  formed  between  the  nitrogen  atom  of  the
ketoximic group in E-configuration and the hydrogen atom of the ortho hydroxyl
group;  the  moiety  made  by rings  A and  B  remembers  the  structure  of  some
polyphenolic  compounds  whose  activity  towards  GLUT1  had  been  identified
(Granchi and Minutolo, 2012).
From docking studies it emerged that the hydroxyl group of the ketoximic
portion results involved in a hydrogen bond with the backbone C=O group of the
Gln397. The OH group in 2 position of the ring B establishes two hydrogen bonds
with the backbone C=O group of Glu146 and the backbone NH group of Arg212.
The introduction of a chlorine atom in 3 position of ring B shows an increase in
the affinity towards the target and it is inserted in a pocket delimited by Ser148
and Arg232 (Granchi et al., 2015).
The aryl substituent (ring C) placed in 4 position of the ring B diminishes
the activity towards estrogen receptor: the values of relative binding affinity of the
series  of  4-aryl-substituted  salicylketoximes  result  very  low  (Minutolo  et  al.,
2009). On the contrary,  these derivatives showed an increased activity towards
GLUT1;  in  particular,  docking  studies  reveled  that  ring  C  is  involved  in  a
lipophilic interaction with Phe460 (Tuccinardi et al., 2013). The effect of R1 and
R2 substituents  on ring C had been tested  investigating  the activity of  several
Figure 14. General structure of 4-aryl-substituted salicylketoximes
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ketoximic derivatives obtained introducing in 4 position variously substituted aryl
substituent.
In figure 15 there are the compounds which show the best results in terms
of glucose uptake and cell viability inhibition; among these molecules, those with
the hydroxyl group in meta or in para position of C ring give the best activity. In
order to allow further biological studies of this class of compounds, during my
thesis I have synthesized compounds 9a, b, e, f, o.
The synthetic pathway used to synthesize compounds  9a,  b,  e,  f,  o. was
developed  by Minutolo  et  al.  for  the  synthesis  of  analogue  ketoximes  active
towards estrogen receptor.
The synthesis is resumed in scheme 1 and 2 showing the main steps of this
pathway (Minutolo et al, 2009).
Figure 15. Structure of the synthesized ketoximic derivatives
Scheme 1. Synthesis of the hydroxyacetone derivative
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The first step of the synthesis consists in the conversion of the commercial
3-bromophenol into the corresponding carbamate (Scheme 3) necessary for the
next step (Sanz et al., 2005).
Commercial 3-bromo-phenol is dissolved in THF and the resulting solution
is added to a solution of NaH in THF: NaH is a strong base able to deprotonate the
phenolic hydroxyl group producing a phenate ione which leads to a nucleophilic
substitution  to  the  carbonyl  of  N,N-diethylcarbamyl  chloride  according  to  an
addition-elimination based mechanism (Scheme 4) resulting in the formation of
the carbamate 10.
Scheme 2. Introduction of the aryl-substituent and conversion of the carbonyl
group into the corresponding ketoxime
Scheme 3. Carbamoylation of 3-bromophenol
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The introduction of the carbamate group is necessary for the following step
which  consists  of  a  lithiation/halogenation  in  ortho position  (Minutolo  et  al.,
2009) (Scheme 5).
The mechanism hypothesized for this reaction is represented in the scheme
6: it involves the formation of a C-Li bond and the successive chlorination using
hexachloroethane as a source of the electrophilic species. (Snieckus, 1990).
Scheme 4. Mechanism of the formation of the carbamate through nucleophilic
substitution
Scheme 7. Hydrolysis of the carbamate 11
Scheme 6. Mechanism of the lithiation followed by the halogenation
Scheme 5. Lithitiation/halogenation on 10
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The base used for the lithiation is LDA which is formed in situ from ( i-
Pr)2NH and  n-BuLi  both  dissolved  in  THF  used  as  solvent  because  of  its
capability  to  coordinate  nBuLi  and  LDA.  The  lithiation/halogenation  is
characterized by good regioselectivitye due both to the direct  ortho metalation
(DoM) effect of the carbamate and to the inductive effect of the bromine atom
(Figure 16).  The DoM effect of a functional group bound to an aromatic ring
(also called “direct metalation group” (DMG) consists in its capability to direct
the metalation in ortho position: this effect is due to the presence in the DMG of
an heteroatom able to  interact  similarly as  a  Lewis  base with  the  metal  atom
(Lewis acid) of the organometallic reagent. On the other hand, the anion species
deriving from the reagent is strong enough to deprotonate the C atom in ortho to
the DMG.
In  this  case,  the  effect  of  the  carbamate  group  is  explained  by  the
coordination  between  the  carbonyl  oxygen  atom and  the  lithium atom in  the
transition state where the oxygen of the carbamate acts similarly as a Lewis base
and  the  lithium as  a  Lewis  acid  (Figure  16).  Moreover,  carbamate  is  poorly
reactive to electophilic species and this situation added to the sterical hindrance
avoids the eventual attack to the DoM group. The reaction is favored also by the
effect of the  meta-bromine atom which increases the acidity of the proton in 2
position due to its inductive effect (Sanz et al., 2005).
The  following  chlorination  is  done  with  the  added  of  hexachloroethane
whose role is to be the source of chlorine atom  (scheme 6) (Kattenberg  et al.,
1973).
Figure 16. Transition state of the direct ortho lithiation.
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The  lithiation/halogenation  allows  a  regioselectivity  that  lacks  in  the
traditional  electrophilic  aromatic  substitution  which  produces  a  mixture  of
halogenated products.
The  carbamate  is  then  removed  through  a  base-catalyzed  hydrolysis  by
using NaOH in EtOH (Scheme 7) (Minutolo et al., 2009).
The  resulting  3-bromo-2chlorophenol  is  used  to  synthesize  the
corresponding acetyl ester using acetyl chloride (Scheme 8).
In the mechanism of the reaction the phenolic group of 12 is deprotonated
by  NaOH  using  TABHS  as  catalyst  and  the  resulting  phenate  ion  is  the
nucleophile that reacts with the acetyl chloride through a nucleophilic substitution
to the carbonyl of CH3COCl (Scheme 9).
Scheme 7. Hydrolysis of the carbamate 11
Scheme 8. Acetylation of the hydroxyl group of 12
Scheme 9. Mechanism of the acetylation of 12
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The following step is the Fries transposition (Scheme 10) consisting in the
arrangement  of  an  arylic  ester  to  an  hydroxyacetophenone  derivative  in  the
presence  of  a  Lewis  acid  (in  this  case  AlCl3).This  mechanism  leads  to  the
migration of the acylic moiety as acylium ion from an oxygen atom to a carbon
atom of the ring giving the ortho substituted compound, although a percentage of
compound para- substituted as by-product is obtained (Minutolo et al., 2009).
The mechanism is represented in  scheme 11:  at first,  a complex between
ester and Lewis acid is formed to eliminate the acylium ion; this electophile reacts
with the aromatic ring in ortho and also in the para position. The high temperature
used for the reaction favors the ortho substituted product, due to the fact that it is
thermodynamically stable thanks to the formation of a six-member pseudo cycle
through intramolecular H-bond (figure 17) with the ortho hydroxyl group.
Scheme 10. Fries transposition on 13
Scheme 11. Mechanism of the Fries transposition
36
The  product  of  the  Fries  transposition  14 is  confirmed  by its  1H NMR
spectrum: in  the spectrum there are  two doublets  relative to  the two aromatic
hydrogen atoms whose mutual  ortho positions are confirmed by a  Jorto = 8.6 Hz
and Jorto = 8.7 Hz. The methyl of the ketonic group is confirmed by the singlet at
2.65 ppm relative to the methyl hydrogen atoms. The singlet at 13.13 ppm belongs
to  the  hydoxyl  hydrogen  revealing  that  its  shift  to  high  value  is  due  to  the
intramolecular H-bond with the carbonyl group; this value conforms to the value
reported in literature (Abraham and Mobli, 2007).
Ring C of the final structure is introduced with the cross coupling reaction
in Suzuki conditions (scheme 12):
This  Pd-catalyzed reaction allows the formation of  a  biphenyl  derivative
starting  from an  aromatic  halide  (compound  14)  and  an  organoboron  reagent
(variously  substituted  phenylboronic  acid).  The  mechanisms  is  shown  in  the
scheme 13 and it is a catalytic cycle involving three steps: oxidative addition,
Figure 17. Intramolecular H-bond in
14
Scheme 12. Cross-coupling in Suzuki condition is used to introduce the aryl-substituents
on 14
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transmetalation  and  reductive  elimination.  The  cycle  starts  with  the  oxidative
addition (a) where Pd(0) is supplied by Pd(PPh3)4 formed in situ from Pd(OAc)2
and PPh3; Pd(0) is added to 14 forming a organopalladium (II) halide complex of
Pd(II).  The  reaction  takes  place  in  position  4  due  to  the  higher  reactivity  of
bromine  halide  then  chlorine  halide  in  these  conditions.  The  next  step  is
transmetalation (b), where the aromatic ring is transferred from the phenylboronic
acid  to  the  palladium  complex;  the  base  increases  the  reactivity  of  the
organoboron compound inducing a negative charge on the boron atom and making
the C-B bound more labile; in this way the organic portion of the phenylboronic
acid is transferred to the Pd(II) displacing the bromine atom and forming a new
complex. The last step is reductive elimination (c) where the C-C bond is formed
between the two ligands giving compounds 15a-e with the simultaneous reduction
of Pd(II) to Pd(0) (Miyaura et al., 1995).
In order  to  obtain the  final  compounds  9a, e,  f,  o the hydrolysis  of  the
methoxy group of ring C is necessary (Scheme 14).
Scheme 13. Mechanism of the cross-coupling in Suzuki
conditions
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The  starting  compound  is  dissolved  in  anhydrous  CH2Cl2;  the  resulting
solution  is  cooled  to  -20  °C  and  a  solution  of  BBr3 is  added.  A possible
mechanism of the reaction can consist the formation of a complex between the
methoxy group  and  the  BBr3 which  confers  a  characteristic  coloration  to  the
reaction  mixture.  The complex is  hydrolyzed  by water  when this  is  added to
quench the reaction before the treatment, thus releasing the free hydroxyl group
(Scheme 15).
Scheme 14. Hydrolysis of the methoxy group of 15a-d
Scheme 15. Mechanism of the hydrolysis with BBr3
Scheme 16. Synthesis of the final ketoximes
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The last step of the synthesis is the conversion of the carbonyl group into
the corresponding ketoxime (Scheme 16) through condensation with NH2OH. The
mechanism is shown in scheme 17.
According to the results reported by Granchi et al., the ketoximes 9a, b, e, f,
o  are obtained in  E-configuration: it is also confirmed comparing the chemical
shift values of the methyl hydrogen atoms (2.25 ≤ δ ≤ 2.41) with the values for
methylketoximes in E-configuration reported in literature (Paterni  et al., 2015).
The intramolecular H-bond between the oximic group and the hydroxyl group is
confirmed by 1H NMR spectrum: in fact, the singlet related to the hydroxyl proton
involved in the intramolecular bond is detected between 12-13 ppm depending of
the  compounds.  The  singlet  related  to  the  oximic  hydrogen  atom is  detected
between 10–11 ppm according to the values reported in literature.
3.7. Biological results of GLUT1 inhibitors
The best synthesized GLUT1 inhibitors were submitted to further biological
assays  by  the  research  group  of  Karin  Lindkvist-Petersson  (Lund  University,
Sweden) (Hansen et al., 2015). In these assays, purified glucose transporter was
reconstituted into giant vesicles capable of reporting its function, thus forming a
simplified  artificial  cell  that  is  able  to  take  up  glucose  and  metabolize  it.
Functional GLUT1 is coupled to an interior enzymatic reaction scheme yielding a
fluorescent  readout  that  is  accessible  by  microscopy.  GLUT1  protein  was
expressed  in  P.  pastoris,  then  cell  membranes  were  isolated  and GLUT1 was
Scheme 17. Mechanism of the conversion of the ketonic group into the
corresponding oximic group
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solubilized from the cell membranes with n-decyl-β-D-maltopyranoside detergent
and  purified  by  anion  exchange  chromatography  and  size  exclusion
chromatography.  Giant  vesicles  were  made  of  1,2-diphytanoyl-sn-glycero-3-
phosphocholine (DPhPC) lipids which form stable lipid bilayers and the entire
system was swollen with buffer containing all the components of an enzymatic
glucose assay. Internalized D-glucose thanks to ATTO390-labeled GLUT1 (cyan,
Figure  18B)  was  converted  to  D-gluconolactone  and  hydrogen  peroxide  by
glucose  oxidase  enzyme (GOx).  Subsequently,  non-fluorescent  Amplex Red is
converted to fluorescent resorufin (red, Figure 18B), in the presence of hydrogen
peroxide, by horseradish peroxidase enzyme (HRP,  Figure 18A). Consequently,
the  fluorescent  reosrufin  signal  (red)  is  confined  within  the  vescicles  and
measurements were performed using a confocal microscope.
In the experiments, the GLUT1-incorporated vesicles were incubated for 5
min with 30  µM inhibitor, then stimulated with 4 mM  D-glucose for another 5
min, followed by imaging. In  Figure 19,  it  is shown the inhibition of glucose
uptake  in  the  giant  vescicle  assay  by  the  synthesized  compounds  and  two
Figure  18. An  artificial  cell  reconstituted  with  GLUT1  and  an
enzymatic  glucose  assay.  (A)  Illustration  of  reaction  scheme.
Facilitative glucose transport by GLUT1 results in conversion of the
internalized  glucose  to  a  fluorescent  resorufin  signal  due  to  the
combined  action  of  GOx  and  HRP  enzymes.  (B)  Fluorescent
micrograph of a real model cell after addition of 4 mM glucose to the
exterior  medium.  ATTO390-labeled  GLUT1  (cyan)  is  clearly
localized in the lipid bilayer membrane, while the interior fluorescent
resorufin signal (red) is confined within the encapsulating membrane.
Scale bar is 10 µm. (Hansen et al, 2015)
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reference GLUT1 inhibitors, cytochalasin B (CB in  Figure 19) and WZB 117.
Ketoximes 9b, 9a, 9e and 9f showed a good inhibition of GLUT1, in particular 9b
and  9e displayed  the  highest  inhibitory  effects,  even  better  than  WZB-117.
Differently, compound 9o was less active, showing a percentage of glucose uptake
similar to control.
Figure 19. Bar graph showing the inhibition of glucose uptake in
giant vescicles assay by ketoxime derivatives and two known 
GLUT1 inhibitors.
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4. LDH-A subunit as potential target in cancer
4.1. Lactate dehydrogenase
One of the main potential target of an anti-metabolic therapy to cancer is
lactate dehydrogenase (LDH). Lactate dehydrogenase catalyzes the reduction of
pyruvate into l- lactate using NADH which is oxidizes into NAD+ (Figure 20).
LDH consists in a  tetrameter whose subunits are distinct in two types that
are LDH-A (or M) and LDH-B (or H) which are codified by two distinct genes,
ldh-a and  ldh-b. There  are  five  isoforms  of  LDH  considering  the  resulting
combination among the subunits named LDH1 to LDH5 (Figure 21). In particular
LDH1 is constituted by four LDH-B subunits, also called LDH-H because this
subunit is located especially in heart whereas LDH5 is constituted by four LDH-A
or LDH-M because it is placed especially in skeletal muscles; LDH2 to LDH4 are
the subunits combination results (Figure 21) (Rani and Kumar, 2015).
Figure 20. Reaction catalyzed by LDH
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Isoforms LDH1 and LDH5 differ for substrate affinity: the latter is more
affinity  to  pyruvate  than  the  former  so  LDH5  catalyzes  mainly  the  pyruvate
reduction to lactate whereas the other enzyme favors the inverse reaction.
The big attention payed on this  enzyme as potential  target  is  due to  the
observation  that  subunit  LDH-A,  and  consequently  LDH5  isoform,  results
overexpressed in highly invasive carcinomas characterized by a strong hypoxic
cancer  cells  component;  due  to  its  characteristic  overexpression  in  tumor,  the
serum and plasma levels of LDH5 are considered as a valid tumor biomarkers.
The  tumor  overexpression  of  LDH-A is  due  to  possible  specific  alterations:
remembering what previously said, c-Myc and HIF-1 allow the encoding of LDH-
A subunit thus explaining the increased presence of this subunit and of LDH5 in
hypoxic cancer cells.  Confirmations to  the importance of LDH in cancer cells
proliferation derives  from silencing of LDH expression through shRNA which
causes a reduction of proliferation; moreover, the inhibition of LDH5 with small
molecule reduces ATP levels and increases oxygen consumption with consequent
ROS generation (Granchi and Minutolo, 2012).
4.2. LDH5 structure
The structure of LDH5 reveals two main domains: one larger that binds the
coenzyme NADH made by aminoacidic residues 20-162 ad 248-266 and a smaller
α/β mixed domain binding the substrate and made by residues 163-247 and 268-
331. An analysis of bind interactions shows that NADH interacts with the enzyme
Figure 21. LDH isoforms 
(Rani and Kumar, 2015)
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at one end of the central β-sheet through His195, Asp168, Arg171 and Thr246; in
particular,  the  nicotinamide  group  partially  overlaps  the  substrate  binding  site
(Rani and Kumar, 2015).
X-rays  crystallography  has  been  used  on  a  ternary  complex  made  by
NADH-  LDH-  pyruvate  showing  that  the  substrate  interacts  via  hydrogen-
bounding  with  Gln99  and  Arg105,  two  residues  of  a  mobile  loop  made  by
aminoacids 96 to 107, the latter considered stabilizing the transition state in the
hydride  transfer  reaction;  Asn137,  Arg169  and  Thr248  which  interacts  with
-COOH  group  of  the  substrate,  in  particular  the  latter  aminoacid  binds  the
carbonylic oxygen of the group and also it binds His193 and Thr248; hydrophobic
interactions exist between the small molecule and Leu164 and Ala237 (Rani and
Kumar, 2015). 
The considerable presence of cationic residues, particularly as arginine, is an
important characteristic of the active site of the enzyme.
4.3. LDH5 inhibitors: background
Initially,  LDH  is  considered  as  a  possible  target  principally  in  malaria
disease (Granchi  and Minutolo,  2012):  in  fact  the etiological  agent  of  malaria
Plasmodium  falciparum lacks  of  the  TCA  cycle  so  glycolysis  is  the  main
important pathway for glucose metabolism. In particular, it is shows that infected
erythrocytes consume of glucose up to two orders of magnitude faster than normal
producing a large amount of lactate as last product of the metabolism. In order to
avoid intracellular acidification and interferences with the oxidation of NADH to
NAD+ the parasite expels lactate through MCTs (Elliott  et al,  2001). Although
some differences exist between pfLDH and hLDH, some molecules developed as
antimalarian  drugs  lack  of  selectivity  thus  showing  a  certain  tendency to  act
towards hLDH; the interactions involving hLDH5 lead to further investigation in
the research of a more selective molecules towards the human enzyme considering
its character as emergent target in cancer therapy (Granchi and Minutolo, 2012).
The  efforts  in  the  development  of  human  LDH5  inhibitors  derive,  as
previous  seen,  from  the  observation  of  its  involvement  in  the  tumor  cells
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metabolism. Moreover, the approach to the LDH5 inhibition for the treatment of
tumor is sustained also by the observation that people with hereditary deficiency
of the  ldh-a genes or patients  with decreased LDH5 activity in  muscles show
myoglobinuria  only after  intense anaerobic exercise as consequence of muscle
damage without any particular symptoms under ordinary circumstances (Granchi
and Minutolo, 2012).
Oxamate  17  (Figure 22) is a pyruvate isoster known for its nonselective
inhibitory activity towards LDH in a competitive manner with the substrate (K i =
138 μM compared with pyruvate). The problem of oxamate is its simple structure:
although it has an affinity for LDH, it results a good inhibitor also for aspartate
aminotransferase. Unfortunately oxamate is characterized by additional unfavored
properties as its weak potency in terms of LDH inhibition and its poor cellular
permeability (Granchi and Minutolo, 2012).
Gossypol 18 (Figure 22) is a polyphenolic binaphtyl sesquiterpene isolated
from  the  cotton  seeds  of  gossypium  that  shows  several  potential  therapeutic
activities. It is able to inhibit both  hLDH5 and Hldh1 in a NADH-competitive
manner respectively with Ki = 1.9 μM and Ki = 1.4 μM (Rani and Kumar, 2015).
Structurally it is characterized by atropoisomerism due to the restricted rotation
around the  C(2)-C(2')  C-C so it  exists  in(R) and (S)  entantiomeric  forms;  the
former  is  found  to  be  more  potent  than  the  latter  showing  a  cytotoxic  effect
characterized by IC50 = 20 μM after tested it in a series of cancer cells culture.
Unfortunately it  has  no clinical  interest  due to  the  lack of  selectivity towards
NAD+-dependent enzymes and to the metabolites derived from the two aldehyde
groups  which  have  nonspecific  toxicity:  in  fact,  gossypol  is  an  higly reactive
redox agent, it can rapidly for Schiff bases and the two aldehyde groups together
with the catechol hydroxyl groups can form polydentate metal-complexing ligand.
Gossypol shows a series of activity in experiments on wild-type and multi-drug
resistance MCF-7 human breast cancer cells not limited to LDH inhibition but
also to NAD+-dipendent enzymes and towards membrane fluidity (Granchi  and
Minutolo, 2012).
 A series of derivatives have been obtained from modification to gossypol
structures.  Starting from  18,  further modifies are done to improve the potency
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maintaining  the  selectivity:  the  result  consists  in  2,3-dihydroxynaphtoic  acid
derivatives. 8-deoxyhemigossylic acid  19  (Figure 22) is the progenitor and the
reference of this family; it displays more selectivity towards hLDH5 than hLDH1
with  Ki =  3.0 μM and Ki =  92 μM respectively.  The higher  selectivity of  19
compared  to  the  corresponding  dimer  deriving  from  gossypol  modifications
shows that only half portion of gossypol scaffold is involved in hLDH5 inhibition
and is sufficient for the required activity.  Compounds with different substituents
are tested and the introduction of benzyl portion in C7 and n-propyl in C4 leads to
compound  20 (FX 11) (Figure 22) characterized by a suitable selective activity
against  hLDH5 in  a  NADH-competitive  manner.  FX 11,  initially enhanced as
potential antimalarian agent, is considered to be a promising anticancer because of
its  capability  to  reduce  ATP  level  and  lactate  production  in  cancer  cells
suppressing  tumor  progression  in  human  lymphoma  and  pancreatic  cancer;
although  these  peculiarity,  the  highly  reactive  catechol  portions  rules  out  the
possibility to develop this substance as drug (Rani and Kumar, 2015).
Another  class  of  LDH5 isoform inhibitors  consist  of  compounds  with  a
polyphenolic  flavone-based structure.  Among these family,  epigallocatechin  21
(Figure 22), extracted from Spatholobus suberectus, shows significant inhibition
on both hLDH5 and HIF-1α eliciting any relevant side effect such as galloflavin
22 (Figure 22), a tricyclic flavone-like molecule that results to be a nonselective
inhibitor of  hLDH5 showing a low cytotoxicity towards healthy cells (Rani and
Kumar, 2015).
Figure 22. Molecules with inhibitory activity towards LDH5
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In  2013  Genetech  (CA,  USA)  discovers  hLDH5  inhibitors  with
dihydropyrimidine  and  pyrazine  scaffolds.  Among  the  dihydropyrimidine
derivatives, the main representative molecule is  23a (Figure 23) which shows a
hLDH5 IC50 = 8.8 μM, similar to  hLDH1 value (IC50 = 11.1 μM); in order to
increase the selectivity, 23a undergoes to several modifications demonstrating the
importance of p-sulfonamide group bound to the aniline ring and the cyano group
for the activity towards  hLDH5 so successful modifications interest the phenyl
ring bound to the dihydropyrimidine scaffold while a methyl or an ethyl group is
introduced on the methylenic carbon (23b-c, Figure 23); in particular, the most
potent compounds are resulted with the insertion of a halogen atom on the phenyl
ring (23d-e, Figure 23).  A series  of  derivatives  exhibit  inhibitory potency till
reaching the nanomolar range (IC50 = 0.48-0.75 μM) towards hLDH5 but showing
at the same time an increased potency towards hLDH1 (IC50 = 2-4 μM) and other
unfavorable properties as for example the poor cell permeability. On the contrary,
pyrazine  derivative  24 (Figure  23)  results  to  be  four  fold  selective  towards
hLDH5 versus hLDH1; further studies display that this compound acts on LDH5
isoform in the presence of NADH interacting with a catalytic residue involved in
substrate catalysis (Rani and Kumar, 2015).
Genetech discovers also the dihydropyrone derivative 25 (Figure 23) with a
significant inhibitory activity against hLDH5 (IC50 = 30 nM) demonstrating good
pharmacokinetic properties as excellent solubility at pH= 7.4, high plasma-protein
binding and lipophylicity. The carbonyl group is shown to interact with His192
via hydrogen bond which results stabilized by a hydrogen bond with Asp165. A
bidentate  hydrogen  bond  results  to  be  formed  between  the  thioether  and  the
carbonyl  group  with  Arg168.  Using  high-throughput  screening  approach,
cyclohex-2-enone 26 and 27 (Figure 23) are disclosed; they are characterized by a
certain selectivity against hLDH5 (IC50 = 0.87 μM and IC50 = 6 nM respectively)
versus  hLDH1.  The  enolic  moiety  of  both  the  compounds  results  to  mimic
oxamate carboxylate group interacting with Arg168 while the ketone form binds
via hydrogen bond His192 and Asp137. Compound 27 is more active than 26 in
fact,  the  former  result  100  folds  more  active  than  the  latter.  The  significant
increasing activity of 27 can be due to the additional interaction between carbonyl
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and the phenyl group of the ester moiety that seems in close proximity with the
protein  via  formation  of  hydrogen  bond  and  partial  π-cation  interactions
respectively (Rani and Kumar, 2015).
Another class of compound is characterized by quinoline-  28  (Figure 23)
and quinolone-based 29 (Figure 23) scaffold with a hydroxyl group in position 4
and a carboxyl group in either the 2- or 3- position. Both the compounds show
marked  activity  on  LDH  over  other  dehydrogenases  and  it  is  observed  that
-COOH  group  confers  high  activity  when  it  is  located  in  3-position  than  2-
position. In these molecule oxamate-like OH-COOH portion is preserved. GSK
modifies the prior compounds introducing an amide or a sulfonamide in the 3-
position,  an  aromatic  amine  in  4-position  and  a  substituted  aromatic  or  a
heteroaromatic ring in 7-position increasing the potency (30, Figure 23). These
compounds  show  bad  pharmacokinetic  properties  thus  hypothesizing  that  the
passage  inside  cells  can  be  due  to  an  active  transport  mechanism (Rani  and
Kumar, 2015).
Bifunctional  molecules  are  characterized  by  two  portions,  one  mimics
substrate structure whereas the other portion mimics the coenzyme. Both these
portions are linked to cover the whole binding pocket of the enzyme. The first of
these compound is  31 (Figure 24): it is obtained through conjugating a glycolic
Figure 23. Molecules with inhibitory activity towards LDH5
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acid to the reduced NADH nicotinamide ring where the α-hydroxic acid portion is
intended to mimic the pyruvate substrate. 31 shows a NADH-competitive activity
on  LDH  in  nanomolar  range  allowing  cardiomyocites  exposed  to  hypoxia-
reoxygenation  stress.  Its  main  problem consists  in  a  lower  permeability.  New
generation  of  chimeric  molecules  (32,  Figure  24)  are  obtained  introducing
bis(indolyl)-maleimide moiety mimicking NADH which show higher selectivity
on hLDH5. (Rani and Kumar, 2015).
Adopting a fragment-based lead generation strategy, AstraZeneca UK has
developed  compound  33 (Figure  24)  which  results  one  of  the  most  potent
bifunctional inhibitors of LDH-A subunit. Its strucure is made by a benzothiazole
ring linked to a malonic portion. Although 33 has characterized by IC50= 0.27 μM,
it  lacks  of cellular  activity probably due to  its  carboxyl  groups that  make the
membrane permeability difficult (Granchi et al, 2014).
4.4. N-hydroxyindole derivative
4.4.1. Introduction to the experimental section
In order to find other possible selective inhibitors of LDH-A subunit, the X-
ray  crystal  structure  of  LDH-A subunit  has  been  studied.  Both  substrate  and
coenzyme binding sites result to be located within the protein; in particular, this
depth region is reach in positive charges as arginine residues thus explaining the
Figure 24. Molecules with inhibitory activity towards LDH5
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role of COOH and OH groups in different molecules as pyruvate (an α-ketoacid),
lactate  (an α-hydroxyacid)  and oxamate in  the bond with the enzyme and the
presence of these functional groups in several LDH5 inhibitors. It appears clear
that  COOH  and  OH  groups  are  required  for  the  affinity  for  the  enzyme.
Considering these pharmacophoric requirements, N-hydroxyindole (NHI) scaffold
is the first unusual detected aromatic scaffold characterized by the disposition of
COOH and OH groups similar to the cited molecules; in particular, the HO-N-C-
COOH fragment remembers HO-C-C-COOH portion of molecules active towards
LDH5 (Figure 25) (Granchi et al, 2011).
In order  to explore the activity of  NHI scaffold for LDH-A subunit  and
consequently  towards  LDH-5  isoform,  a  series  of  compounds  had  been
synthesized (Figure 26) (Granchi et al, 2011).
Figure 25 Endogenous substrates of LDH and molecule with inhibitory activity
towards LDH5
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The importance of the N-hydroxyl group was evaluated studying the activity
of the by-product  of reductive cycization for  the synthesis  of  36  (38) and the
synthesized O-methylated derivative 39 (Figure 27) (Granchi et al, 2011).
All the compounds have been tested in order to define their activity towards
both LDH-A and LDH-B subunits, using respectively LDH5 and LDH1 isoforms.
Even the simple 34 showed a modest inhibitory activity towards both the subunits.
Among the tested derivatives, the most interesting were 35, 36, 37, which showed
a  higher  activity  towards  LDH-A than  LDH-B  subunit.  It  was  seen  that  the
introduction of a phenyl susbstituent in position 4 caused the drop of the activity
while  the introduction in position 5 or 6 (36)  increased the activity observing
better result than 34; the substitution of Ph with heterocycles as a tethrazole ring
caused a decrease of the activity.  The introduction of an electron withdrawing
group had  been  tested,  for  example  positioning  CF3 group  in  4  position  (35)
obtaining,  although  still  present,  a  decreased  inhibition  of  LDH-B  and  an
increased inhibition of LDH-A. Compound with CF3 in 4 and Ph in 6 position (37)
Figure 26. Some of the N-hydroxyindole derivatives tested for their inhibitory
activity towards LDH-A subunit
Figure 27. Derivatives that confirms the importance of N-OH group
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showed a higher activity on LDH-A and a negligible effect on LDH-B (Granchi et
al, 2011).
Regarding the modifications on  N-OH motif, the indole  38 had a modest
activity towards both the subunits while the O-methylated ether 39 resulted to be
inactive. (Granchi et al, 2011).
In the light of these observations, 36 and 37 had been chosen to investigate
their  type  of  inhibitions  resulting  in  the  competition  with  both  cofactor  and
pyruvate for the bound with the enzyme. Among the three compounds, 37 seems
to be the most selective towards LDH-5 isoform (Ki= 8.9 μM vs NADH and Ki=
4.7 μM vs pyruvate).
Therefore, all the compounds are investigated for the entity of the reduction
of lactate/glucose ratio and 37 reduced the ratio to values < 0.01. After experiment
in vitro, 36 and 37 result to be selectively cytotoxic and it was observed that their
effect increases under hypoxia (Granchi et al, 2011).
Also the activity of methyl esters 40 (Granchi et al, 2011) and 41 (Granchi
et al, 2013) were tested in comparison with the corresponding free acid 36 and 37
respectively (Figure 28).
The  first  ester  was  isolated  as  by-product  of  the  reductive  cylization
necessary  to  obtain  compound  36;  it  was characterized  by  modest  inhibitory
activity  towards  both  the  subunits  if  compared  with  the  corresponding  acid
(Granchi et al, 2011).
The  ester  41 had  been  synthesized  after  the  results  observed  with  37.
Compound 41 showed a discrimination between the two subunits resulting from 4
to 7 folds more active towards LDH-A than LDH-B. Comparing the uptake of
both compounds, it emerged that the concentration of 41 inside HeLa cells lysate
Figure 28. Tested methylester derivatives
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was 4 fold  higher  than  that  of  37 (Figure 29)  and,  in  the  lysate,  the ester  is
observed in its non-hydrolyzed form (Granchi et al, 2013).
 Moreover,  41 caused  a  strong  reduction  in  lactate  production  then  the
corresponding free acid, probably due to its high absorption in tumor cells (Figure
30) (Granchi et al, 2013).
In conclusion, the methylation of COOH did not consist in a masking into a
prodrug but it leads to a compound with an own inhibitory activity towards LDH-
A subunit (Granchi et al, 2013).
Figure 29. Intracellular concentration of compound 37
(blue) and the related methyl ester 41 (red). Values are
expressed in terms of concentration relative to compound
37 (Granchi et al, 2013)
Figure 30. Effect on lactate production by 37 (blue) and 41 (red) at various
concentration (Granchi et al, 2013)
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As  previous  described,  hypoxic  tumor  cells  are  characterized  by  an
increased  glucose  uptake  mediated  by  overexpressed  GLUT1.  The  glucose-
conjugation  takes  advantage  of  this  altered  glucose  uptake  to  increase  the
concentration of these compounds inside tumor cells (“dual targeting” strategy);
thus,  with  this  purpose,  compounds  42 and  43 are  synthesized  (Figure  31)
(Calvaresi et al, 2013).
42 and  43 underwent to an inhibition assay done on the isolated enzyme
showing that the conjugation decreases the potency of the compound of 2- and 7-
fold  respectively  if  compared  to  their  respective  aglycons.  These  glucose-
conjugated were also tested with their corresponding aglycons 37 and 41 on HeLa
cells that are characterized by the overexpression of both GLUT1 and LDH5: it
was observed that 42 results inactive, with a IC50> 200 μM, while 43 results 3-5
folds and 6-9 folds more potent respectively than 41 and 37 (table 3) (Calvaresi et
al, 2013).
Compounds In vitro Ki values vs NADH
in LDH-A
Toxicity on HeLa cell
line
IC50 (μM)
37 10.8 ± 2.6 43.8 ± 4.6
41 5.1 ± 1.1 33.4 ± 1.0
42 19.5 ± 3.0 -
43 37.8 ± 0.9 7.2 ± 0.2
Table 3. Values of the compounds tested for the “dual targeting” strategy
(Calvaresi et al., 2013)
Figure 31. Synthesized glucose-conjugated for the "dual targeting" strategy
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In the  proliferation  assay  42 demonstrated a  modest  effect  similar  to  37
while 43 showed a dose-dependent reduction of lactate production resulting to be
more potent than its aglycone 41.
A549 cells had been used to evaluate the capability of glucose-conjugate 43 to be
transported inside the cells comparing it to the absorption of  37 and 41: the cell
line was treated with compounds  37,  41 and the glucose-conjugated  43 at  the
same concentration: the measurement of the concentration of each compounds in
the lysate cells showing that the aglycone  41 resulted 4.5 folds more adsorbed
than  the  corresponding  acid  while  the  glucose-conjugated  43 presented  a
concentration  24  folds  higher  that  42.  The  transport  through  GLUT1  was
confirmed  by  a  competition  assay  performed  between  43 and  GB2-Cy3,  a
fluorescent  Cy3-linked  glucose bioprobe  that  is  able  to  compete  for  glucose
enhancing fluorescence; also 37 was tested in the same assay. The results showed
that no diminution of fluorescence was detected in the assay of  37 while it was
strongly reduced in the assay of 43 thus confirming the competition for GLUT1.
An interesting observation is the fact that after the absorption 43 did not appear to
be highly cleaved into the corresponding free acid 37 or into the free aglycon 41;
on the contrary, the glucose portion was found to be involved in interactions in the
NADH-binding pocket. In brief, the increased absorption of glucose conjugated
43 compensated its lower inhibition potency on the isolated target resulting in a
suitable example of dual targeting (Calvaresi et al, 2013).
4.4.2.  Synthesis  of  the  glucose-conjugated  N-hydroxyindole
derivative
In the light of the results derived from the assays done on the series of N-
hydroxyindole derivatives synthesized by the research team of the Univeristy of
Pisa, compound 41 and its glucose-conjugated 43 show promising results and in
order  to  further  study  in  vitro and  in  vivo their  activity,  I  synthesized  the
mentioned compounds (Figure 32).
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The synthetic pathway of this compound starts from the synthesis of the N-
hydroxyindole  derivative  (Granchi  et  al.,  2011)  followed  by  its  glycosylation
(Calvaresi et al, 2013) (Scheme 18).
The first step of the synthesis consists in the iodination of commercial 2-
methyl-1-nitro-3-(trifluoromethyl)benzene using N-iodosuccinimide (Hume et al.,
2002) which allows the iodination of deactivated aromatic compounds as in this
case (Olah et al., 1993).
Scheme 18. Synthetic pathway used to obtain 43
Figure 32. The synthesized N-hydroxyindole derivative 41 and its
corresponding glucose-conjugated 43
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At first, the N-iodosuccinimide is dissolved in concentrated H2SO4 in order
to form the electrophilic species 48 (Scheme 20) that reacts with the added starter
compound through an electrophilic aromatic substitution.
The resulting iodo-derivative  44 is  used for  a  cross  coupling reaction in
Suzuki  conditions  in  order  to  introduce  the  phenyl  substituent  (Scheme  21)
(Granchi  et al., 2011); the mechanism is the same described for the synthesis of
the salicylketoximic derivatives but  in this  case the aromatic  halide is  a iodo-
derivative which is also reactive in this conditions:
The resulting biphenyl  45 is used to synthesize the ketoester  46 (Scheme
22).
Scheme 19. Synthesis of the iodo-derivative 44
Scheme 20. Formation of the electrophilic species
Scheme 21. Cross-coupling in Suzuki condition on 44
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 t-BuOK is the base used to deprotonate the methyl group of the biphenyl
producing a  nucleophilic  species  which  reacts  with  the  oxalate  dimethyl  ester
(Scheme 23).
The formation of the ketoester is confirmed by the 1H NMR spectrum which
shows the signal related to the protons in α position to the aromatic ring. This
compound is in balance with its enol form (Figure 33): in particular, the spectrum
shows the peak of the ketonic form at 4.71 ppm corresponding to the two protons
in α position and also the corresponding peak of the CH group of the enol form at
6.19 ppm. The percentage of the enolic form is 16% and it is calculated on the
base of the peaks of the protons in α position in both the forms.
Scheme 23. Mechanism of the formation of the ketoester 46
Scheme 22. Synthesis of the ketoester 46
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The  resulting  ester  46 is  cyclized  to  obtain  the  indole  ring  through  a
reductive cyclization with SnCl2 (Katayama et al., 2001). The nitro group of the
starting compound is reduced to hydroxylamine and a condensation takes place
between the this group and the carbonyl group of the side chain, finally forming
the heterocycle (Scheme 24) (Katayama et al., 2001).
In the step of the cyclization, an amount of 1-H-indole as by-product derives
from the total reduction of -NO2 to amine and subsequent cyclization and it is
detected from TLCs under  UV lamp (λ = 365 nm).  The singlet  at  10.49 ppm
integrating for one proton corresponds to the N-hydroxy group hydrogen atom.
The  N-hydroxindole  derivative  41  is  the  aglycon  portion  of  the  final
product.
Figure 33. Tautomerism of the ketoester 46
Scheme 24. Reductive cyclization of 46
Scheme 25. Glycosylation of 41
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The  next  step  is  the  glycosylation  using  acetobromo-α-D -glucose  as
glycosyl donor (Scheme 25); the base-catalyzed reaction of O-glycosylation is a
nucleophilic substitution in 1 position of the glycosyl donor performed by N-OH
group of the aglycone. In particular, the stereoselectivity of the reaction is also
favored  by the  anchimeric  assistance  of  the  acetyl  group in  2 position  of  the
glucose (Scheme 26).
The  purification  of  the  glucose-conjugated  consists  in  the  fractionate
crystallization: a little volume of lukewarm AcOEt is added to the crude product
to obtain a solution which is filtrated in a flask; then, some  n-hexane is slowly
added to the solution until a clouding is noted. At least, the flask is covered with
aluminum foil and it is left overnight. When the crystallization is happened, the
mixture is filtrated with a bell jar to gather the solid using  n-hexane to wet the
flask.
Therefore, in order to obtain compound 43, the acetyl groups of the sugar 
portion are methanolyzed using a solution of MeONa/MeOH 25%. The 
purification of the product consists in the trituration: a volume of Et2O is added to 
the solid product and it is scratched to dissolve possible impurities since the 
glucose-conjugate is not soluble in the solvent. At least, the solid is gathered after 
filtration. The 1H NMR spectrum shows that the solid consists in a mixture of 47 
with by-products as mono-acetylated derivative and the free acid of 43. In order to 
hydrolyze the last acetyl esters, another methanolysis is done obtaining mixture 
again but this time between 43 and the related free acid.
Scheme 26. Purposed mechanism of the glycosylation
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The  selective  methylation  of  the  carboxylic  acid  with  TMS-CHN2 is
performed to restore the methyl ester but after several additions of the reagent, the
TLC reveals that the mixture between the ester and the corresponding free acid is
still present. Considering this situation, we decide to attempt the purification of 43
with flash chromatography on silica gel establishing specific conditions that allow
a  rapid  purification  and  a  limited  permanence  time  of  the  compound  in  the
column: the most suitable condition consists in the use of an eluent mixture made
by CHCl3:  MeOH = 9:1;  moreover  the  solubility  of  the  compound  in  MeOH
avoids its adsorption on silica gel so the crude product is dissolved in a small
volume of eluent mixture to be introduced in the column. This purification results
to be able to purify the desired product with a final yield of 61%.
Subsequently, we tried to purify the final product 43 from the methanolysis 
step with flash chromatography in the same condition. Surprisingly, the product 43 
results to be purified with high yields.
 The 1H NMR spectrum confirms that the expected β-configurated product is
obtained, as suggested by the doublet at 5.22 ppm that could be related to the
proton in the C1 of the glucose characterized by J = 8.0 Hz.
4.5. N-hydroxybenzimidazole derivative
4.5.1. Introduction to the experimental section
In order to investigate the activity of  N-hydroxybenzimidazole derivatives,
during  my  period  of  thesis  I  try  to  synthesize  a  6-phenyl-substituted  N-
hydroxybenzimidazole derivative.
Bearing in mind the N-hydroxyindole structure and considering the activity
of the NHI-based compounds, Yue and Wang enhanced some derivatives of  N-
hydroxybenzimidazole as  N-hydroxyindole isoster, on the basis of the properties
of some  N-hydroxyenzimidazole derivatives (Yue and Wang, 2015). The theory
behind the attention payed towards this scaffold consists in the research of new
binding  interaction  if  possible  due,  in  this  case,  to  the  presence  of  a  second
nitrogen  atom with  an  available  electron  pair.  In  this  work  the  derivative  48
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(Figure 34) has been synthesized in order to study its activity towards LDH-A
subunit.
4.5.2. Synthesis of N-hydroxybenzimidazole derivative
N-hydroxybenzimidazole is an isoster of N-hydroxyindole; both the activity
of the latter compound towards LHD5 isoform and the presence of benzimidazole
scaffold  in  different  marketable  drugs  offer  the  opportunity  to  enhance  the
research about the possible activity of  N-hydroxybenzimidazole towards LDH5.
For this reason, during my period of thesis, I tried to synthesize the 6-phenyl N-
hydroxybenzimidazole derivative (Figure 35).
The interactions between  N-hydroxyindole and LDH-A subunit have been
previously  described,  similarly  the  N-hydroxybenzimidazole  derivative  was
docked into the active pocket of LDHA and the results show as the  N-OH and
-COOH groups interact with residues of the pyruvate binding pocket (Yue  and
Wang, 2015).
The synthetic pathway used to obtain the compound is developed by Yue
and Wang (Scheme 27).
Figure 34. Synthesized N-hydroxybenzimidazole derivative
Scheme 27. Synthetic pathway used for the synthesis of 48
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The  first  step  consists  in  the  synthesis  of  the  biphenyl  49 starting  from
commercial 4-bromo-1-fluoro-2-nitrobenzene and using the phenylboronic acid to
introduce  the  phenyl  substituent.  The  reaction  is  a  cross  coupling  in  Suzuki
conditions and the mechanism of the reaction is the same of that described for the
synthesis of GLUT1 inhibitors. Interestingly, the 1H NMR spectrum of compound
49 the coupling between the aromatic proton and the fluorine atom are visible.
The next  step  consists  of  a  nucleophilic  aromatic  substitution  where  the
nucleophilic species is methyl glycynate to give 50. The reactivity of 49 is favored
by the C-F bond which is strongly polar and subsequently the carbon atom results
more susceptible to the nucleophilic attack; moreover the presence of the nitro
group in ortho position favors the reaction because its inductive effect increases
the electrophilicity of the carbon atom and its mesomeric effect is able to stabilize
the negative charge of the intermediate. The mechanism of the reaction is showed
in the scheme 30.
The  confirmation  of  50  derives  from the  1H NMR spectrum where  the
coupling with the fluorine atom disappears and the glycinate portion is confirmed
by a singlet at 3.85 ppm integrating for 3 protons related to the CH3 of the ester
group and the doublet at 4.17 ppm integrating for 2 protons related to the protons
in α position of the glycinate portion.
The resulting ester undergoes to a base-catalyzed reductive cyclization using
MeONa as base (Yue  and Wang, 2015). The treatment of the reaction mixture
consists in the extraction with Et2O; several extractions have been done due to the
Scheme 30. Mechanism of the nucleophilic substitution on 49
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formation  of  a  precipitate  not  soluble  in  neither  of  the  two phases  remaining
located in corresponding of the interphase. Because of its unknown identity, it is
gathered in the aqueous phase in order to not contaminate the product. Thus, the
resulting  organic  phase  is  washed with  brine  and dried.  The crude  product  is
purified with flash chromatography to obtain a small amount of the product of the
cyclization 51.
In  order  to understand the composition of  the precipitate,  we decided to
extract  the  aqueous  phase  with  AcOEt  observing  that  the  precipitate  results
weakly soluble in this solvent and for this reason several extractions with this
solvent are done. The resulting organic phase is dried, filtrated and concentrated;
the  undissolved  sizable  amount  of  precipitate  present  in  the  aqueous  phase  is
filtrated with a bell jar.
The 1H NMR spectra in MeOD of the product purified by column and the
precipitate are compared and surprisingly the spectra have the same profile so the
two products result to be the same compound, corresponding to the product of the
cyclization. 
The last passage is the base-catalyzed hydrolysis of the ester 51 to obtain the
free acid 48. The aqueous phase is neutralized using 1N aqueous HCl in order to
re-protonate the carboxylic acid group and then an extraction with AcOEt is done
observing the formation of precipitate in corresponding of the interface between
the two phases, similarly to the situation encountered in the prior step. For this
reason, the aqueous phase is extracted several times with AcOEt until it results
limpid and all  the precipitate  is  gathered.  The resulting organic phase appears
cloudy. Io order to dissolve the suspended solid, a little bit of MeOH is added to
the organic phase; after this, the crude product is dried, filtrated and concentrated.
A white solid is obtained and it results to be the acid 48.
4.5.3. Results and discussions
In the 1H NMR spectrum of ester 51 in CD3OD, the singlet of the methoxy
group is detected, as well as the signals related to the eight aromatic protons; in
order to confirm the presence of the N-OH group, we obtain a 1H NMR spectrum
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in  DMSO-d6 observing the presence of a  broad singlet  at  12.49 ppm (Yue  et
Wang, 2015).
The  13C NMR done in CD3OD confirms the presence of methoxy carbon
atom at 53.26 ppm, the presence of aromatic carbon atoms in the range 109.31
ppm – 142.10 ppm and finally the signal at 159.50 ppm could be related to the
carbon atom of the ester group.
As  reported  in  literature,  N-hydroxybenzimidazole  derivatives  are
characterized by a tautomeric equilibrium with their corresponding  N-oxides. In
solution, the prevalence of one form on the other is related to the characteristics of
the solvents: in particular, in H-bonds donor solvents as DMSO and acetone, the
N-oxide tautomer is favored, while the balance is shifted to the N-hydroxy in H-
bonds  acceptor  solvents.  Moreover,  1H  NMR  spectra  in  CDCl3  of  several  2-
substituted  N-hydroxybenzimidazole derivatives reveal that  substituents able to
establish  intramolecular  H-bonds,  as  2-carboxiamide,  could  favor  the  N-oxide
form even in H-bonds acceptor solvents (Boiani et al, 2004).
Although the 1H NMR spectrum of the ester 51 in CD3OD seems to confirm
the presence of the N-hydroxy tautomer, small peaks of aromatic hydrogen atoms
are detected in the range 7-8 ppm probably related to the N-oxide tautomer. The
1H NMR spectrum of 51 reacquired in DMSO-d6 reveals the apparent prevalence
Figure 35. Tautomerism in N-hydroxybenzimidazole derivatives and examples of
intramolecular H-bonds with 2-substituent
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of N-hydroxy tautomer: this hypothesis can be confirmed comparing the chemical
shifts values of hydrogen in 4 and 7 position with the values reported by Boiani et
al. and by the disappearance of the weak peaks presents in the spectrum acquired
in CD3OD.
Bearing  in  mind  as  reported  in  literature,  the  difficult  solubility  of  the
compounds  51 and  48 probably  could  be  due  to  the  intermolecular  H-bonds
forming among the close molecules of the product in the precipitate (Boiani et al,
2004).
The last step of the synthetic pathway shows the same problem of the prior 
step relative to the formation of an insoluble precipitate. 1H NMR spectrum of 48 
is performed in DMSO-d6 in which the solid results soluble. The peak related to 
the protons of the methoxy group of the ester  51 are not detected while all the 
aromatic  protons  peaks  result  visible.  Regarding  the  protons  bound  to  the 
heteroatoms, two singlets integrating for one proton are visible at 8.50 ppm and 
12.18 ppm, the latter resulting as a broad signal, hypothesizing that these signals 
belong respectively to the carboxyl proton and to the proton of the N-hydroxy 
group. In order to confirm this hypothesis, the spectrum is performed adding D2O 
observing the disappearance of the peak at 12.18 ppm but the peak at 8.44 is still 
visible; an hypothesis thought to explain the presence of the peak at 8.44 ppm is 
that the carboxylic group has a slowly time of exchange with the solvent. For this 
reason, the spectrum was reacquired after 1h from the addition of the D2O showing 
that the peak is still visible. In the light of these facts, it was supposed that the 
signal at 8.44 ppm belongs to the hydrogen of the N-oxide form, since N-OH 
derivative 48 is in balance with the N-oxide form; also it was hypothesized that the 
carboxylic hydrogen atom is involved in an intramolecular hydrogen bond with the 
heterocycle nitrogen atom (Figure 35). In order to understand the source of the 
signal at 8.44 ppm, a HSQC spectrum was acquired showing that the proton 
signals at  8.44 ppm of the  1H NMR spectrum in DMSO-d6 was related to the 
signal at 140.23 ppm of the  13C NMR spectrum. Comparing these values with 
those reported by Boiani  et al., it was hypothesizing that the signal at 8.44 ppm 
could correspond to an aromatic proton of the N-hydroxy tautomer.
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In conclusion,  the  signal  relative to  the  carboxyl  proton is  not  detected;
considering  the  weak  signal  relative  to  the  N-hydroxyl  proton  it  was
hypothesizing that the signal of the carboxyl proton is lost in the ground noise.
Surprisingly, in the 1H NMR spectra of 48 weak peaks are visible probably
related to the N-oxide form; among these peaks, the most visible signal imputable
to  the  N-oxide  tautomer  is  the  singlet  around  8.12  ppm as  confirmed  by the
difference between the chemical shifts values of the N-oxide and N-hydroxy forms
reported by Boiani et al.
However, NMR spectra data are not sufficient in order to establish exactly
the predominant form of the compound in solution.
4.6. Biological results of LDH inhibitors
Currently, further biological studies in vitro and in vivo of the synthesized 
LDH inhibitors 41 and 43 are underway. 
N-hydroxybenzimidazole  48 was  tested  in  enzymatic  experiments  on the
human isoform of  LDH5,  but  it  proved  to  be  inactive,  therefore  the  different
chemical structure of this compound deeply affects the activity on the enzyme,
despite  the  high  homology  between  the  N-hydroxybenzimidazole  and  the  N-
hydroxyindole scaffold.
Compound Structure
hLDH5
IC50 (NADH-Pyr)
48 inactive
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5. LOX as target to inhibit tumor invasiveness
5.1. LOX is involved in ECM modifications
As previous  said,  extracellular  matrix  (ECM) plays  an  important  role  in
metastasis because it influences cancer progression; several mechanisms have the
purpose  to  preserve  the  integration  of  the  ECM  and  an  alteration  of  these
mechanism can result in altered ECM as seen in diseases as fibrosis and cancer
(Lu et al, 2012).
ECM  has  a  heterogeneous  composition  consisting  in  several
macromolecules as for example proteins, glycoproteins, proteoglycans each with
specific  properties.  The  organization  of  these  macromolecules  influences  the
properties  of ECM: for example,  its  stiffening changes with the disposition of
collagen fibers with subsequent alteration in cellular migration. Collagen is one of
the main component of ECM: this  protein is classified in several types on the
basis  of  the  disposition  of  its  fibers.  In  particular,  many evidence  confirm its
increased deposition during tumor formation and the resulting increased stiffness
of tumor stroma is found to characterized invasive tumor phenotypes (Lu  et al,
2012).
Lysyl  oxidase  (LOX)  is  an  enzyme  that  catalyzes  cross-linking  between
collagen fibers determining ECM structure (Figure 36) and for this reason this
enzyme is subjected to several studies in order to evaluate if its activity could be
correlated with the characteristic observed in tumor stroma.
Figure 36. Reaction catalyzed by LOX (Lucero and Kagan,
2006).
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LOX is secreted as proprotein which is cleaved by proteases to release the
active form. LOX emerges as an N-glycosylated proprotein.  The propeptide is
characterized by two sites for N-glycosylation. The mature form contains 10 Cys
residues existing as disulfide linkage and a histidine-rich sequence represents the
copper-binding  site  involved  in  the  copper-dipendent  catalyst.  The  secreted
proLOX has no activity till  it  is  activated by proteolytically cleavage between
Gly162 and Asp163 by several proteases as procollagen C-proteinase; the number
of proteases potentially involved in LOX maturation represents the importance of
the control of LOX activity in ECM homeostasis. In order to explain its activity, it
is  important  that  fibrillar  collagen  is  secreted  as  procollagen  species  which
presents  both  N-  and  C-terminal  propeptide  domains  on  each  of  its  three
component α chain polypeptides. The form of type I collagen susceptible to LOX-
catalyzed  oxidation  requires  both  the  prior  removal  of  N-  and  C-procollagen
propeptides  by  N-  and  C-procollagen  proteinases  as  well  as  the  subsequent
aggregation of mature collagen molecules into microfibrilles. Both LOX and its
substrate are converted in the mature form by the same protease. LOX catalyzes
also  the  oxidation  of  tropoelastin,  the  secreted  precursor  of  insoluble  elastin,
leading to insoluble elastin deposits, a characteristic of the connective tissue. It is
observed that the activation of proLOX takes place on the fibroblasts surface after
forming a complex with fibronectin (FN) (Lucero and Kagan, 2006).
For  its  activity,  LOX needs of  two cofactors:  copper  as  Cu2+ and  lysine
tyrosylquinone (LTQ) (Figure 37) which autocatalytically derived from specifics
tyrosine and lysine residues within the nascent enzyme.
Figure 37. Lysyne tyrosyiquinone (Lucero and
Kagan, 2006).
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The mechanism of action of LOX (Figure 38) has been studied in detail: the
ε amino group of lysine residue condenses with the two carbonylic groups of LTQ
and the  resulting  linkage of  the  Shiff  base  coupled  with  general  base-assisted
abstraction of a hydrogen atom on carbon 6 of the substrate Lys residue permits
the flow of two electrons into LTQ generating the reduced peptidyl lysine tyrosyl
aminoquinol.  The  hydrolysis  of  the  resulting  imine  linkage  releases  α-
aminoadipic-δ-semialdehyde  (AAS)  product  from  the  reduced  cofactor.  The
subsequent re-oxidation of the peptidyl aminoquinol occurs by the transfer of two
electrons  to  molecular  oxygen,  forming and releasing  hydrogen peroxide.  The
resulting quinoneimine is then hydrolyzed to regenerated LTQ and to release the
free ammonia product of the reaction.(Lucero and Kagan, 2006).
Even in some cases the generation of AAS can alter the structure of local
macromolecules influencing the interactions between proteins or between protein-
nucleic acids; this can also happen through the action of ROS or free radicals but,
on the contrary of LOX catalysis, they can non-selectively oxidize lysyl residues. 
In vitro assays demonstrate that LOX oxidizes not only collagen and elastin
as initially hypothesized but it can also oxidize several proteins with pI> 8.0, so
electrostatic  potential  between  the  acid  protein  LOX  and  the  base  peptidic
substrate  is  essential  to  catalysis.  Successive  studies  shows  that  among  the
possible substrates of LOX there are also not-peptidyl amines. 
Figure 38. Mechanism of action of LOX (Lucero and Kagan, 2006).
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The effect of the positive charge on the potential substrate seems to reflect
the charge distribution of anionic residues within LOX which results to be located
in the vicinity of the active site of the enzyme. Although the three-dimensional
structure of LOX has not be clearly identified, it  is noted that the two regions
containing respectively Tyr345 and Lys314, involved in the formation of LTQ, are
enriched of anionic residues; after LTQ formation, these two regions result to be
cross-linked and their close results in a higher anionic charge concentration that
explain LOX affinity to basic proteins. As previous said, the two main substrates
of  LOX  are  tropoelastin  and  collagen:  tropoelastin  is  a  cationic  molecule
seemingly appropriate to the electrostatic features of the specificity of LOX while
the  sequences  surrounding  susceptible  Lys  in  collagen  are  in  hydrophylic
sequences containing anionic residues and this fact results in an impediment to
access to LOX due to negative charge of the aminoacidic residues. This fact also
reveals the importance of the collagen molecules condensation into microfibrilar
which is the form susceptible to LOX catalysis probably due to the presence of
positive  charges  that  neutralized  the  negative  charge  hold  LOX action  on  the
protein.
LOX has also other functions: in fact, it can act as a chemotaxic factor when
it is secreted in its active form: this activity is related both on human peripheral
blood mononuclear cells and on vascular smooth muscle cells (VSMCs). H2O2
produced by the enzyme seems to play a role  in  the chemotaxis because it  is
observed that the LOX-inducted chemotaxis on VSMCs end with the addiction of
catalase to the cellular culture. In particular, the effect of LOX on VSMCs consists
in  an  increased  stress  fiber  formation  after  improved  H2O2 production  and
increased focal adhesion assembly (Lucero and Kagan, 2006).
Several  techniques  have  shown that  an  intracellular  form of  LOX exists
which is located in the nucleus retaining its catalytic activity. In particular, histone
H1 is found to be a LOX substrate according to the high concentration of lysyne
in its structure and to the cross-linking level in the presence of the oxidse; it is
hypothesized  that  LOX  activity  can  influence  histone  H1-DNA  interaction
(Lucero and Kagan, 2006).
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5.2. Hypoxia-induced LOX in tumor tissues
Metastasis  has  be  found  to  be  clinically  associated  to  hypoxia  but  this
correlation is still unclear. In particular, HIF-1 seems to promote the encoding of
several proteins involved in the different steps promoting cancer cells migration.
Among these proteins there is LOX: in fact the concentration of this enzyme
appears to be increased under hypoxia and HIF seems to regulate its expression.
Moreover,  several  works  show a relationship between LOX-mediated collagen
crosslinking and tumor enhancing and metastasis  tendency.  Among the several
cases, in breast cancer and head-neck cancer the oxidase level is increased and
generally  patients  with  elevated  LOX-espressing  tumor  have  a  lower  distant
metastasis-free survival (Erler and Giaccia, 2006).
Different studies have confirmed that LOX is involved in several functions
which can promote tumor invasiveness. 
In particular, a functional hypoxia-responsive elements (HRE) is found in
LOX promoter  thus  demonstrating  the  role  of  HIF in  altered  LOX level  (the
hypoxia-increased LOX mRNA expression results in increased level of secreted
LOX and its activity). The LOX involvement in metastasis is observed studying
the effects of the enzyme inhibition: results suggest that there are not association
between tumor size and metastases number and LOX inhibition,  moreover  the
blocked activity of the oxidase does not have major activity on primary tumor
growth; on the contrary, LOX activity levels in blood are reduced. Cancer cells
from control, characterized by high LOX level, show higher tendency to invasion
than cell  lines with LOX shRNA. Increased invasion under hypoxic or anoxic
condition compared to cells in normoxic conditions results to be inhibited after
treatment with BAPN or shRNA. Considering that lysyl oxidase is placed both in
extracellular and intracellular space, decreased invasion is obtain after alteration
of  cancer  cells  culture  medium  with  a  copper  chelator  which  acts  only  on
extracellular  enzyme  suggesting  a  major  role  from  extracellular  LOX.  In  air
presence, the three-dimensional culture of cancer cells show that control lines are
characterized by a branching architecture of the entire culture while cells with
LOX shRNA culture maintain a spheroidal form; these results are enhanced in
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oxygen deprivation. Another observation consists in the role of LOX in invasive
cells motility: cancer cells can move thanks to pseudopodes protrusion with the
leading edge driven by actin polymerization resulting in focal adhesion complex
formation and the activation of integrin and FAK. Hypoxia leads to an increased
phosphorylation of FAK resulting in a higher focal adhesion complex formation
and in a cytoskeleton re-modeling with higher stressed fibers. In particular, LOX
expression is increased on the longhair like fibers protruding from cells surface
into the collagen matrix; all these observations lack in LOX shRNA cancer cells
(Erler and Giaccia, 2006).
Hypoxia is shown to increase the amount of secreted LOX acting also on
collagen fibers outside the cancer cells thus increasing the integrin activity which
results in an improved cells movement; migrating cells left behind them an altered
ECM that can be used for other possible migration. These events are the result of
LOX and LOX-induced FAK. 
Moreover, the HIF-1 itself results able to stimulate the encoding of proper
hydroxylases necessary to obtain the collagen fibers configuration required for
LOX catalysis (Gilkes and Semenza, 2013). 
A characteristic of metastatic lesion is the presence of inflammatory cells; in
particular,  LOX is  found to be involved in  the premetastatic  niches formation
which  comprise  a  series  of  inflammatory  cells  as  bone  marrow-derived  cells
(BMDCs) that form a cell cluster preceding tumor cells arrival. Chemotaxic action
of LOX increases  the concentration of these cells  as monocytes  cells  in these
districts.  Premetastatic  niches  also show to  produce  high  level  of  fibronectine
wich can actvate proLOX in mature form (Gilkes and Semenza, 2013).
The survival of metastases in the new districts is also guaranteed by HIF-1
and by enzymes encoded by it.
5.3. LOX as target
β-aminoproprionitrile (BAPN) 52 (Figure 39) is extensively studied: it is an
irreversible LOX inhibitor taken as reference in LOX studies.
74
Its  proposed  mechanism  of  action  consists  in  the  competition  with  the
substrate  thus  forming  an  imine  group with  the  coenzyme;  in  the  step  of  the
hydrolysis,  a nucleophilic substitution occurs in corresponding of the  β carbon
atom thus resulting in the formation of a covalent bond (Tang et al, 1983)
In order to evaluate the activity of BAPN on metastatic cancer cells, it is
administered daily to mice starting either 1 day prior, on the same day as, or 7
days after intracardiac cells injection of MDA-MB-231-Luc2 cells which express
luciferase.  The  metastasis  development  in  vivo is  monitored  trough
bioluminescence imaging while tumor-induced osteolysis is assessed by micro-
computed tomography. BAPN results to be able to decrease tissue colonization by
MDA-MB-231-Luc2 cells. In particular, BAPN pretreatment significantly reduces
not  only  number  of  metastasis  but  also  the  whole  animal  tumor  burden
(Bondareva et al, 2009).
The  results  suggest  that  BAPN is  active  during  the  initial  phase  of  the
extravasion  process.  In  this  experiment,  an  elevated  number  of  metastses  are
introduced in mice through intracardial injection and BAPN results to be able to
reduce their  number.  Considering the fact  that  the concentration of circulating
tumor is lower than experimental conditions, BAPN reveals a promising results.
In particular, BAPN shows to prevent metastases formation due to its capability to
reduce metastasis  formation without effect on tumor growth (Bondareva  et al,
2009). 
Although its promising results, it lacks of selectivity towards the target.
Figure 39. β aminoproprionitrile
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5.4.Introduction to the experimental section
As previous seen, BAPN is extensively used as reference in LOX inhibition
assays  due  to  its  affinity  for  this  enzyme;  unfortunately  it  can  not  displays
eventual  clinical  uses  because  of  its  too  simple  structure  resulting  in  a  non-
specific activity  in vivo. A strategy considered to enhance the therapeutic use of
BAPN  consists  in  mask  it  to  obtain  prodrugs  with  the  purpose  to  avoid  the
interaction of BAPN with other enzymes that could resulting in side effects.
Several mechanisms of the release of active molecules from prodrgus are
reported in literature; in hypoxic conditions, the reductive activation is a suitable
strategy of activation.
The selective activation of this compounds under hypoxia is favored by the
shortage  of  oxygen  because  this  condition  implies  a  pronounced  activity  of
different  reductases  (Chen  and  Hu,  2008).  In  general, these  prodrugs  were
designed  to  be  activated  by  endogenous  one-electron  or  two-electrons
oxidoreductases  which  are  able  to  reduce  the  masking  moiety  under  hypoxia
allowing the release of the active drug. In particular, one-electron oxidoreductases
generally catalyze oxygen-dependet reduction: in normxic condition, oxygen can
compete for the single electron of the initial reduced drug species and its capture
prevents the activation of prodrugs. Thus, oxygen is converted into superoxide
radicals which are finally eliminated by superoxide dismutases. On the contrary,
in hypoxia, the competition of oxygen is avoided so these enzymes can activate
the prodrugs. This characteristic could confer a selective release of the active drug
in hypoxic tissues and an oxygen-mediated deactivation in normal tissues (Guise
et al., 2014).
Among the  different  categories  that  can  be activated  under  hypoxia,  the
research team of the University of Pisa has developed some BAPN prodrug using
the nitroaromatic masking moiety (Figure 40 and 41) (Granchi et al., 2009).
The  general  structure  of  these  prodrugs  and  its  main  components  are
represented in figure 40: 
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 the masking moiety is a nitro-aromatic substituent which can consist in a
nitro-aryl (X=C and n=2) or in a nitro-heteroaromatic cycle (X=O, n=1);
nitro group is placed in para and also in ortho to the side chain;
 a linker portion which is a methylene group or a methoxycarbonyl group;
 the active drug consisting in BAPN.
Figure 41. Prodrugs synthesized by Granchi et al (Granchi et al., 2009)
Figure 40. General structure of prodrugs
synthesized by Granchi et al.
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The proposed mechanism of activation of these potential prodrugs consists
in the activation through elimination (figure 42): nitro group is reduced in the
corresponding  hydroxylamine  group  which  undergoes  to  a  spontaneous  1,6-
elimination releasing the active BAPN. SAR studies on nitroaromatic prodrugs
reveal that the presence of an electron-withdrawing group as nitro group decreases
the selectivity towards hypoxia increasing the activity under aerobic conditions,
on  the  contrary  the  reduction  of  nitro  to  hydroxylamino  group  which  is  an
electron-donating group has the advantage to decreases both aerobic and hypoxic
activity but increasing the selectivity towards the latter condition (Chen and Hu,
2013).
The activation of these prodrugs produces a by-product consisting in a high-
reactive  electrophilic  species  characterized  by  short  life  that  could  have  a
contribute in the inhibition of LOX (Granchi et al, 2009).
The  tendency  to  the  bioreductive  activation  was  studied  with  a  cyclic
voltammetry analysis. The nitro group is reduced to hydroxylamine according to
the  detected  values  of  reduction  potentials:  in  fact  all  the  four  compounds
produced a reproduction peak when the potential was scanned for 0.0 → -1.8 V
(vs. Ag/AgCl) corresponding to the four-electrons four-protons reduction of nitro
Figure 42. Mechanism of activation of prodrugs 53-56 (Granchi et al., 2009)
Figure 43. Activation of prodrug 56
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group to hydroxilamine.  The molecules with the aryl aromatic portion showed
similar  reduction  potential  values  in  the  range  from -0.74  to  -0.77  while  the
nitrofuran derivative exhibited a minor value (-0.61 V) (Granchi et al, 2009).
In order to study the activity of these compounds towards LOX and their
selectivity in hypoxia conditions, biological assays had been done in comparison
to BAPN. Results are reported in figure 44.
The activity towards LOX was controlled monitoring the fluorescence under
both  normoxia  and  hypoxia;  56 and  55 showed  the  best  results  in  terms  of
selectivity. In this test, compound  54 was not tested due to its photolability that
caused interference with the assay. The diminution of the metastasis was seen in
vitro using  MDA-MB-231  cell  lines  resulting  that  the  compound  with  the
nitrofuryl masking portion is more selective because the level of invasion in air
was not altered; on the contrary 55 caused a certain decrease in the invasiveness
also  in  normoxic  cells  although  it  was  also  selective.  The  worst  result  was
represented by 53 which showed a marked inhibition of the invasiveness of cells
with air while compound  56 results to be the most selective thus inhibiting the
invasiveness specificly in hypoxic condition (Granchi et al., 2009).
The promising results of 56 encourages the investigation about the activity
of other nitro substituted five-member ring masking moiety also in the attempt to
avoid the side effect of nitrofuryl derivative due to its genotoxicity.
Figure 44. Results of the fluorescence measurements and invasivness inhibition
(Granchi et al, 2009)
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5.5. LOX inhibitor synthesis
The biological assays done on the series of nitroaromatic prodrugs revealed
that the nitrofuranmethyl moiety was characterized by selectivity towards hypoxic
conditions if compared with the other three molecules of the series (Granchi et al.,
2009).
Therefore,  encouraged  by  the  results  obtained  with  nitrofuranmethyl
prodrug, the research team of the University of Pisa decided to investigate about
the  effect  derived  from  the  use  of  other  nitro-substituted  five-member
heterocycles.  In  particular,  during  my  period  spent  in  the  laboratory,  I  have
synthesized a nitrotiophenemethyl prodrug as hydrochloride salt  57 (Figure 45)
which is an isoster of the nitrofuranmethyl prodrug described in the prior section.
In this compound the masking moiety is a nitrotiophene and the linker portion
consists once again in a methylene.
The synthetic pathway used to obtain 20 is the same used by Granchi et al.
(Scheme 30).
Figure 45. Prodrug with nitrothiophene masking
moiety
Scheme 30. Synthetic pathway used to obtain 57
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The  first  step  of  the  reaction  is  the  reductive  amination.  At  first,  a
condensation takes place between the primary amino group of BAPN and the
aldehydic  group  of  5-nitrothiophene-2-carbaldehyde  to  form  the  imine  58
(Scheme 31) 
Generally aromatic aldehydes results less reactive then their corresponding
aliphatic compounds but in this  case the presence of the electron withdrawing
nitro  group  increases  the  reactivity  of  the  carbonyl  carbon  atom towards  the
nucleophile BAPN.
The  resulting  imine  is  not  purified  but  the  reaction  mixture  is  directly
treated with NaBH4 to reduce the imine to the corresponding amine (Scheme 32).
It is interesting to note that a change of the mixture’s color was visible due to the
disappearance of the conjugation between the two chromophore groups consisting
in the nitrothiophene group and the iminic group.
The reduction is done at -20 °C using a bath of water, ice and NaCl due to
its exothermic character. The mixture is stirred for 30 min; after this period, the
mixture is quenched and a TLC reveals the presence of a mixture between the
starter  imine  and  the  product.  The  purification  of  the  crude  results  in  the
separation of the amine 22 and the starter imine which results to be stable.
Scheme 31. Mechanism of the formation of the imine 58
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 The structure of 58 is confirmed by the 1H NMR spectrum which shows a
multiplet  at  8.41  ppm integrating  for  one  proton and  probably relative  to  the
iminic hydrogen atom.
The amine 59 is confirmed by the appearance of a signal integrating for two
protons at 4.06 ppm consisting in a doublet, probably relative to the two protons
in α position to the aromatic ring, characterized by a long-range coupling with the
aromatic proton in ortho at the side chain (4J = 0.9 Hz). In the 1H NMR spectrum
there is not any signal relative to the aminic proton.
The resulting amine is finally converted in the corresponding hydrochloride
salt (Scheme 31): the amine is dissolved in dry MeOH and a commercial solution
of Et2O·HCl is dropped until a precipitate is formed; the use of Et2O·HCl also
simplifies the purification of the product.
The purification is made with the filtration of the reaction mixture with a
bell jar washing it with Et2O.
The 1H NMR spectrum of the salt shows a profile similar to the amine but
the signals are located to higher fields probably due to the deshielding effect of
the  positive  charge  on  the  nitrogen  atom.  The  presence  of  the  tiophene  is
Scheme 32. Mechanism of the reduction of the imine
Scheme 31. Salification of 57
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confirmed by the signals of the two aromatic protons consisting in two distinct
doublets each integrating for one proton and located respectively at 7.32 ppm (2J =
4.2 Hz) and 8.00 ppm (2J = 4.2 Hz); moreover, the four aromatic carbon atoms are
detected in the 13C NMR spectrum.
5.6 Biological results of LOX inhibitors
The  newly  synthesized  pontetial  LOX  inhibitor  57 is  currently  being
evaluated for LOX inhibition and antiproliferative activity against cancer cells by
Dr. Elisa Giovannetti, at the VU Amsterdam.
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Conclusion
Hypoxia  is  a  condition  that  makes  difficult  the  survival  of  cells.  The
adaption of cells to this condition are mediated by HIFs, a transcription factors
group which  is  normally active only under  hypoxic condition.  In  solid  tumor,
when tumor mass growth, hypoxia can occur and although specific mechanisms
control the activity of HIF, in tumor cells this control results altered.
In particular, HIF-1 allows the encoding of specific proteins as transporter
and enzymes that sustain the survival of cells in this drastic condition. In hypoxic
region of solid tumor, HIF-1 is responsible of modifications regarding both the
cellular  metabolism  and  their  capability  to  migrate  that  can  be  related  to
aggressive phenotypes.
The modification induced on cellular metabolism consists in its switch from
the  oxidative  phosphorylation  to  the  aerobic  glycolysis,  also  called  “Warburg
effect”;  this  deviation  can  occur  even  in  the  presence  of  oxygen,  in  order  to
prepare  cells  to  its  shortage.  Although  this  condition  can  be  considered
disadvantageous, it  satisfies all the requirements necessary for cells  growth. In
particular, HIF-1 increases the encoding of specific enzymes that play important
roles in the aerobic glycolysis: among them, isoform GLUT1 is overexpressed
thus  increasing  the  uptake  of  glucose;  on  the  other  hand,  subunit  LDH-A,
therefore LDH5 isoform, also results overexpressed thus allowing the oxidation of
NADH even in shortage of oxygen in order to restart the metabolic pathway. Their
inhibition can caused cellular death for starvation. 
The other modification induced by hypoxia in tumor cells is related to their
invasivenss: in fact HIF-1 can increase the production of VEGF thus stimulating
the angiogenesis and producing blood vessels that lack of selective permeability.
In  this  context,  lysyl  oxidase  (LOX)  is  an  enzyme  normally  involved  in  the
modelling  of  the  extracellular  matrix  but  it  also  results  overexpressed  under
hypoxic condition in several types of tumors and it seems to be involved in their
metastatic  potential.  As  seen,  the  inhibition  of  LOX  strongly  reduces  the
metastatic colonization potential of cancer cells.
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The overexpression of these specific protein in tumor cells offers, in theory,
the opportunity to attack them in a selective manner.
This  work  is  focused  on  the  attempts  of  the  synthesis  of  different
compounds developed as inhibitor of some of these specific proteins.
GLUT1 (Figure 46) inhibitors derive form molecules initially developed as
ER inhibitors. The synthesized salicylketoximes show promising results in terms
of inhibition of glucose uptake and cell viability.
LDH5 inhibitors consists in an N-hydroxyindole derivative (Figure 47) and
in an N-hydroxybenzimidazole derivative (Figure 48). The former compound is a
glucose-conjugated  whose  activity  towards  the  enzymes  has  been  studied
revealing that it inhibits selectively LDH5; although it results less potent then its
aglycone, it has developed to takes advantage from GLUT1 expression in cancer
cells resulting in an increased intracellular concentration.
During the synthesis  of this  glucose-conjugated,  an encountered problem 
was the purification of the final product from a mixture made by products of 
partial methanolysis of glucose’s acetyl ester and product derived from the 
hydrolysis even of the aglycon ester; in order to optimize the purification of the 
final product, a flash chromatography is attempted: the use of an eluent mixture of 
CH3Cl: MeOH= 9:1 allows a rapid purification with yields of in the range 60-
80%.
Figure 46
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The  N-hydroxybenzimidazole  derivative  has  developed  as  isoster  of  the
aglycon of the previous compound. Its synthesis results more difficult due to the
insolubility  of  the  final  product  and  of  its  corresponding  methyl  ester  in  the
organic solvents used for the treatments of the different steps. NMR spectra reveal
the tautomerism between the N-hydroxy/ N-oxide; the prevalence of one form on
the other and especially the H-bonds formed could have influenced the solubility
in the organic solvents.
The unselectivtiy of BAPN activity leads to the development of potential
bioreductive  prodrugs.  In  this  work,  a  potential  prodrug has  been synthesized
which  is  characterized  by  a  masking  portion  consisting  in  a  nitrothiophene
(Figure  49).  The  choice  of  this  masking  portion  derived  from the  promising
results observed with the use of nitrofuryl masking portion.
Figure 47
Figure 48
Figure 49
86
Experimental procedures
Materials and methods
All the reactions were monitored using thin-layer chromatography (TLC)
using Merck aluminum silica gel (60 F245) sheets that were visualized under a UV
lamp (254 nm; 365 nm). Anhydrous sodium sulfate was used as drying agent.
Flash  chromatography  on  silica  gel  was  performed  using  silica  gel  60.  The
structures of the compounds were verified with  1H NMR and  13C NMR spectra
obtained  with  Bruker  Avance  III  HD  operating  at  400  MHz  spectrometer.
Chemical shifts (δ)  values are expressed as ppm and coupling constants (J) are
expressed in Hz. The following abbreviations were used to explain the signals: s =
singlet, d = doublet, t = triplet, m = multiplet, dd = double doublet, ddd = double
double doublet, bs = broad singlet.
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Compound 10
In a flame-dried two-necked flask 832 mg (34.7 mmol) of NaH are stirred in
17.3 mL of THF. Apart, 3g (17.3 mmol) of 3-bromophenol are dissolved in 4.3
mL of THF and the resulting solution in added to the flask. The mixture is stirred
for  3h.  Then,  a  solution  prepared  dissolving  4.4  mL(35  mmol)  of  N,N-
diethylcarbamoylchloride  in  6.1  mL of  THF  is  added.  The  mixture  is  stirred
overnight.
The treatment consists in the pH neutralization with 1N aqueous HCl and in
the extraction with AcOEt; the organic phase is washed with brine, dried, filtrated
and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 95:5). 4.60 g (16.9 mmol) of the product are obtained as a yellow
liquid. 
The yield of the reaction is 98 %.
1H NMR (400 MHz, CDCl3), δ (ppm);
1.16-1.28 (m, 6H); 3.36-3.45 (m, 4H);7.05 (ddd, 1H, Jorto= 8.2 Hz, Jmeta= 2.1
Hz, Jpara= 1.2 Hz); 7.22 (t, 1H, Jorto= 8.4 Hz); 7.31- 7.34 (m, 2H).
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Compound 11
In a flame-dried two-necked flask, under argon, 1.49 mL (10.6 mmol) of
(iPr)2NH are dissolved in 28.8 mL of dry THF of at 0°C and 6.61 mL of 1.6 M
nBuLi solution are added. The mixture is stirred at 0°C for 30 min. Then, the LDA
solution is cooled at -78°C using a dry ice/acetone bath and 2.6 g (9.6 mmol) of
10 are added. The mixture is stirred at  this temperature for 30 min. After this
period, C2Cl6 (2.72 g, 11.5 mmol) are added to the flask at -78°C. After 30 min the
mixture is warmed to RT.
The reaction is quenched with water and THF is evaporated under reduced
pressure. The mixture is extracted with AcOEt, washed with brine and dried. The
organic phase is filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 9:1). 1.04 g (3.39 mmol) of the product are obtained. The yield of
the reaction is 35 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
1.22 (t, 3H, 3J= 7.1 Hz); 1.30 (t, 3H, 3J= 7.2 Hz); 3.40 (q, 2H, 3J= 7.1 Hz);
3.49 (q, 2H, 3J= 7.0 Hz); 7.13 (t, 1H, JABC= 8.1 Hz); 7.19 (dd, 1H, Jorto= 8.1 Hz,
Jmeta= 1.6 Hz); 7.48 (dd, 1H, Jorto= 7.9 Hz, Jmeta= 1.6 Hz).
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Compound 12
In a flame-dried two-necked flask, under argon, 713 mg (2.33 mL) of 2 are
dissolved in 23.3 mL of EtOH. 932 mg (23.3 mmol) of NaOH are added to the
solution.  The  mixture  is  heated  at  100  °C  and  refluxed  at  this  temperature
overnight. The treatment starts with the evaporation of EtOH; then, the residue is
diluted with Et2O at 0 °C and the pH is neutralized with 1 N aqueous HCl. The
mixture is extracted with AcOEt, washed with brine and dried. The organic phase
is filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 85:15) and 599 mg (2.89 mmol) of the product are obtained as a
blue liquid. 
The yield of the reaction is > 99 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
5.91 (exchangeable, s, 1H); 6.98 (dd, 1H, Jorto= 8.2 Hz, Jmeta= 1.6 Hz); 7.05
(t, 1H, Jorto= 8.2 Hz); 7.19 (dd, 1H, Jorto= 8.0 Hz, Jmeta= 1.6 Hz).
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Compound 13
In a flame-dried two-necked flask 1.41 g (6.81 mmol) of 12 are dissolved in
10.18 mL of dioxane, in sequence NaOH (654 mg, 16.3 mmol) and TBAHS (7.4
mg, 0.02 mmol) are added to the solution. The mixture is stirred for 30 min. Then,
a solution of acetyl chloride (0.56 ml, 7.83 mmol) in dioxane (6.26 mL) is added.
After 60 min the reaction is quenched with ice water and the mixture is extracted
with  AcOEt,  washed with  brine  and dried.  The  organic  phase  is  filtrated  and
concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 9:1) to obtain 1.10 g (4.41 mmol) of the product as an oily liquid.
The yield of the reaction is 65 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.36 (s, 3H); 7.11 (dd, 1H, Jorto= 8.1 Hz, Jmeta= 1.6 Hz); 7.16 (t, 1H, Jorto= 8.0 
Hz); 7.53 (dd, 1H, Jorto= 7.9 Hz, Jmeta= 1.6 Hz).
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Compound 14
371 mg (1.49 mmol) of  13 are treated with 258 mg (1.94 mmol) of AlCl3
and the mixture is heated at 130 °C. After 3h the vial is cooled at RT, the mixture
is treated with 1 N aqueous  HCl and extracted with AcOEt; the organic phase is
washed with brine, dried over Na2SO4, filtrated and concentrated.
The crude product is purified with a flash chromatography on silica gel (n-
hexane:AcOEt= 95:5). 265 mg (1.06 mmol) of the product are obtained as a white
solid. 
The yield of the reaction is 71 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.65 (s, 3H); 7.22 (d, 1H,  Jorto= 8.6 Hz); 7.53 (d, 1H,  Jorto= 8.7 Hz); 13.13
(exchangeable, s, 1H).
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Compound 15b
16 mg (0.06 mmol) of PPh3 are dissolved in EtOH (0.75 mL) and toluene
(0.75 mL) in a vial under argon; then, 2.69 mg (0.012 mmol) of Pd(OAc)2 are
added. The mixture is stirred for 10 min.
After this period, 150 mg (0.6 mmol) of 14, 0.75 mL of 2 M Na2CO3(aq) and
119 mg (0.78 mmol) of (3-methoxyphenyl)boronic acid are added in sequence.
The mixture is heated at 100 °C and stirred at this temperature overnight.
Before  the  treatment,  the  mixture  is  cooled  at  RT  and  the  reaction  is
quenched with water; then, the mixture is extracted with AcOEt and washed with
brine. The organic phase is dried, filtered and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 95:5). 125 mg (0.45 mmol) of the product are obtained as yellow
liquid. 
The yield of the reaction is 75 %.
1H NMR (400 MHz, CDCl3), δ(ppm):
2.69 (s, 3H); 3.85 (s, 3H); 6.92-6.94 (m, 1H); 6.95-7.04 (m, 3H); 7.38 (td, 
1H, Jorto= 8.0 Hz, Jpara= 0.7 Hz); 7.71 (d, 1H, Jorto= 8.3 Hz); 13.08 (exchangeable, s,
1H).
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Compound 16b
In  a  flame-dried  two-necked  flask  125  mg  (0.451  mmol)  of  15b are
dissolved in 5.23 mL of anhydrous CH2Cl2 and the solution is cooled to -20 °C.
1.35 mL of BBr3 are added in the flask. The mixture is stirred at -20 °C for 5 min.
Then the flask is heated at 0°C and left in this condition for 1h.
After that the mixture is cooled at RT, the reaction is quenched with water
and the treatment proceeds with the extraction with AcOEt; the organic phase is
washed with brine, dried, filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 8:2).  80.1 mg (0.305 mmol)  of the product  are  obtained.  The
yield of the yield 68 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2,69 (s, 3H); 4.95 (exchangeable, bs, 1H); 6.88-6.93 (m, 3H); 7.00 (ddd, 1H,
Jorto= 7.6 Hz,  Jmeta= 1.5 Hz,  J= 1.0 Hz); 7.33 (t, 1H,  Jorto= 8.0 Hz); 7.70 (d, 1H,
Jorto= 8.3 Hz); 13.08 (exchangeable, s, 1H).
94
Compound 9b
A solution of 7 (80 mg, 0.31 mmol) in EtOH (5.83 mL) is treated with an
aqueous solution of NH2OH·HCl (1.4 mL, 0.61 mmol). The mixture is heated at
50 °C and it is stirred at this temperature for 48 h. After this period, the mixture is
cooled to RT, EtOH is evaporated and the resulting phase is diluted with water;
then,  it  is  extracted with AcOEt and washed with brine.  The organic phase is
dried, filtrated and concentrated.
The crude product  is  purified with a  flash chromatography on silica  gel
(CH2Cl2:MeOH= 98:2). 59.9 mg (0.216 mmol) of the product are obtained. The
yield of the reaction is 71 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.41 (s, 3H); 6.87-6.93 (m, 4H); 7.28 (td, 1H, Jorto= 7.6 Hz, Jpara= 0.5 Hz);
7.57 (d, 1H, Jorto= 8.2 Hz); 8.48 (exchangeable, bs, 1H); 10.95 (exchangeable, bs,
1H); 12.42 (exchangeable, s, 1H).
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Compound 15c
16 mg (0.06 mmol) of PPh3 are dissolved in EtOH (0.75 mL) and toluene
(0.75 mL) in a vial under argon; then, 2.7 mg (0.01 mmol) of Pd(OAc)2 are added.
The mixture is stirred for 10 min.
After this period, 150 mg (0.6 mmol) of 14, 0.75 mL of 2 M Na2CO3(aq) and
130 mg (0.78 mmol) of (4-methoxy-3-methylphenyl)boronic acid are  added in
sequence.  The  mixture  is  heated  at  100  °C  and  stirred  at  this  temperature
overnight.
Before  the  treatment,  the  mixture  is  cooled  at  RT  and  the  reaction  is
quenched with water; then, the mixture is extracted with AcOEt and washed with
brine. The organic phase is dried, filtered and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 95:5).  124 mg (0.425 mmol) of the product are obtained as a
yellow solid. The yield of the reaction is 70 %.
1H NMR (400 MHz, CDCl3), δ (ppm);
2.28 (s, 3H); 2.68 (s, 3H); 3.89 (s, 3H); 6.91 (d, 1H, Jorto= 8.5 Hz); 6.92 (d,
1H, Jorto= 8.3 Hz); 7.26 (s, 1H); 7.31 (dd, 1H, Jorto= 8.4 Hz; Jmeta= 2.0 Hz); 7.68 (d,
1H, Jorto= 8.3 Hz); 13,1 (exchangeable, s, 1H).
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Compound 16c
In a flame-dried two-necked flask 124 mg (0.42 mmol) of 15c are dissolved
in 4.9 mL of anhydrous CH2Cl2 and the solution is cooled to -20  °C. 1.3 mL of
BBr3 are added in the flask. The mixture is stirred at -20 °C for 5 min. Then the
flask is heated at 0 °C and left in this condition for 1h.
After that the mixture is cooled at RT, the reaction is quenched with water
and the treatment proceeds with the extraction with AcOEt; the organic phase is
washed with brine, dried, filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 8:2).  81.8 mg (0.294 mmol)  of the product  are  obtained.  The
yield of the yield 70 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.26 (s, 3H); 2.73 (s, 3H); 6.93 (d, 1H, Jorto= 8.2 Hz); 6.98 (d, 1H, Jorto= 8.3
Hz); 7.18 (ddd, 1H, Jorto= 8.2 Hz, Jmeta= 2.3 Hz, J= 0.5 Hz); 7.25 (dd, 1H, J= 2 Hz,
J=  0.8  Hz);  7.94  (d,  1H,  J=  8.3  Hz);  8.55  (exchangeable,  s,  1H);  13.13
(exchangeable, s, 1H).
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Compound 9o
A solution of 16c (82 mg, 0.29 mmol) in EtOH (5.54 mL) is treated with an
aqueous solution of NH2OH·HCl (1.3 mL, 0.58 mmol). The mixture is heated at
50°C and it is stirred at this temperature for 48h. After this period, the mixture is
cooled to RT, EtOH is evaporated and the resulting phase is diluted with water;
then,  it  is  extracted with AcOEt and washed with brine.  The organic phase is
dried, filtrated and concentrated.
The crude product  is  purified with a  flash chromatography on silica  gel
(CH2Cl2:MeOH= 98:2). 55 mg (0.19 mmol) of the product are obtained. The yield
of the reaction is 65 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.25 (s, 3H); 2.4 (s, 3H); 6.88 (d, 1H, Jorto= 8.2 Hz); 6.89 (d, 1H, Jorto= 8.2
Hz); 7.13 (ddd, 1H, J= 8.2 Hz, J= 2.3 Hz, J= 0.5 Hz); 7.20 (dd, 1H, J= 2.2 Hz, J=
0.5  Hz);  7.53  (d,  1H,  J=  8.3  Hz);  8.42  (exchangeable,  bs,  1H);  10.40
(exchangeable, bs, 1H); 12.38 (exchangeable, s, 1H).
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Compound 15a
16 mg (0.06 mmol) of PPh3 are dissolved in EtOH (0.75 mL) and toluene
(0.75 mL) in a vial under argon; then, 2.7 mg (0.01 mmol) of Pd(OAc)2 are added.
The mixture is stirred for 10 min.
After this period, 150 mg(0.6 mmol) of 14, 0.75 mL of 2 M Na2CO3(aq) and
119 mg (0.78 mmol) of (4-methoxyphenyl)boronic acid are added in sequence.
The mixture is heated at 100 °C and stirred at this temperature overnight.
Before  the  treatment,  the  mixture  is  cooled  at  RT  and  the  reaction  is
quenched with water; then, the mixture is extracted with AcOEt and washed with
brine. The organic phase is dried, filtered and concentrated.
The crude product is  purified with flash chromatography on silica gel(n-
hexane:AcOEt=  9:1).  113  mg (0.481 mmol)  of  the  product  are  obtained  as  a
yellow solid. 
The yield of the reaction is 68 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.68 (s, 3H); 3.87 (s, 3H); 6.92 (d, 1H, J= 8.3 Hz); 6.99 (2H, AA'XX', JAX=
8.9 Hz, JAA'/XX'= 3.0 Hz); 7.43 (2H, AA'XX', JAX= 8.8 Hz, JAA'/XX'= 3.0 Hz); 7.69 (d,
1H, J= 8.3 Hz); 13.10 (exchangeable, s, 1H).
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Compound 16a
In a flame-dried two-necked flask 113 mg (0.41 mmol) of 14 are dissolved
in 4.7 mL of anhydrous CH2Cl2 and the solution is cooled to -20 °C. 1.23 mL of
BBr3 are added in the flask. The mixture is stirred at -20 °C for 5 min. Then the
flask is heated at 0°C and left in this condition for 1h.
After that the mixture is cooled at RT, the reaction is quenched with water
and the treatment proceeds with the extraction with AcOEt; the organic phase is
washed with brine, dried, filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 8:2). 81 mg (0.31 mmol) of the product are obtained. The yield of
the reaction is 76 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.74 (s, 3H); 6.96 (2H, AA'XX', JAX= 8.7 Hz, JAA'/XX'= 2.8 Hz); 6.99 (d, 1H,
J= 8.3 Hz); 7.37 (2H, AA'XX', JAX= 8.6 Hz, JAA'/XX'= 2.8 Hz); 7.95 (d, 1H, J= 8.3
Hz); 8.66 (exchangeable, s, 1H); 13.13 (exchangeable, s, 1H).
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Compound 9a
A solution of 14 (81 mg, 0.31mmol) in EtOH (5.93 mL) is treated with an
aqueous solution of NH2OH·HCl (1.4 mL, 0.62 mmol). The mixture is heated at
50 °C and it is stirred at this temperature for 48h. After this period, the mixture is
cooled to RT, EtOH is evaporated and the resulting phase is diluted with water;
then,  it  is  extracted with AcOEt and washed with brine.  The organic phase is
dried, filtrated and concentrated.
The crude product  is  purified with a  flash chromatography on silica  gel
(CH2Cl2:MeOH= 98:2). 65.9 mg (0.237 mmol) of the product are obtained. The
yield of the reaction is 77%.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.40 (s, 3H); 6.90-6.94 (m, 3H); 7.32 (2H, AA'XX', JAX= 8.8 Hz, JAA'/XX'= 2.8
Hz); 7.54 (d, 1H, J= 8.3 Hz); 8.55 (exchangeable, bs, 1H); 10.90 (exchangeable,
bs, 1H); 12.39 (exchangeable, s, 1H).
101
Compound 15e
16 mg (0.06 mmol) of PPh3 are dissolved in EtOH (0.75 mL) and toluene
(0.75 mL) in a vial under argon; then, 2.7 mg (0.01 mmol) of Pd(OAc)2 are added.
The mixture is stirred for 10 min.
After this period, 150 mg (0.6 mmol) of 14, 0.75 mL of 2 M Na2CO3(aq) and
133  mg (0.78  mmol)  of  (3-fluoro-4-methoxyphenyl)boronic  acid  are  added  in
sequence.  The  mixture  is  heated  at  100  °C  and  stirred  at  this  temperature
overnight.
Before  the  treatment,  the  mixture  is  cooled  at  RT  and  the  reaction  is
quenched with water; then, the mixture is extracted with AcOEt and washed with
brine. The organic phase is dried, filtered and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 9:1).  146 mg (0.494 mmol)  of  the  product  are  obtained  as  a
yellow solid. The yield of the reaction is
82 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.75 (s, 3H); 3.96 (s, 3H); 7.03 (d, 1H, J= 8.3 Hz); 7.23-7.33 (m, 3H); 7.99
(d, 1H, J= 8.3 Hz); 13.13 (exchangeable, s, 1H).
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Compound 9b
A solution of 15e (144 mg, 0.49 mmol) in EtOH (9.4 mL) is treated with an
aqueous solution of NH2OH·HCl (2.2 mL, 0.98 mmol). The mixture is heated at
50 °C and it is stirred at this temperature for 48h. After this period, the mixture is
cooled to RT, EtOH is evaporated and the resulting phase is diluted with water;
then,  it  is  extracted with AcOEt and washed with brine.  The organic phase is
dried, filtrated and concentrated.
The crude product is purified with a flash chromatography on silica gel (n-
hexane:AcOEt= 9:1). 120 mg (0.386 mmol) of the product are obtained. The yield
of the reaction is 76 %.
1H NMR (400 MHz, MeOD), δ (ppm):
2.35 (s, 3H), 3.92 (s, 3H); 6.89 (d, 1H, J= 8.2 Hz); 7.13-7.21 (m, 3H); 7.49
(d, 1H, J= 8.3 Hz).
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Compound 15d
16 mg (0.06 mmol) of PPh3 are dissolved in EtOH (0.75 mL) and toluene
(0.75 mL) in a vial under argon; then, 2.7 mg (0.01 mmol) of Pd(OAc)2 are added.
The mixture is stirred for 10 min.
After this period, 150 mg (0.6 mmol) of 14, 0.75 mL of 2 M Na2CO3(aq) and
145 mg (0.78 mmol)  of  (3-chloro-4-methoxyphenyl)boronic  acid  are  added in
sequence.  The  mixture  is  heated  at  100  °C  and  stirred  at  this  temperature
overnight.
Before  the  treatment,  the  mixture  is  cooled  at  RT  and  the  reaction  is
quenched with water; then, the mixture is extracted with AcOEt and washed with
brine. The organic phase is dried, filtered and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 85:15). Two fractions are obtained and one of this is a mixture
made of the product and other by-products. The amount of the pure fraction is
60.1 mg (0.193 mmol).
The yield of the reaction is calculated considering the pure fraction and it is
32 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
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2.69 (s, 3H); 3.97 (s, 3H); 6.90 (d, 1H, J= 8.3 Hz); 7.01 (d, 1H, J= 8.6 Hz);
7.37 (dd, 1H, J= 8.5 Hz; J= 2.0 Hz); 7.50 (d, 1H, J= 2.2 Hz); 7.70 (d, 1H, J= 8.3
Hz); 13.09 (exchangeable, s, 1H).
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Compound 16d
In a flame-dried two-necked flask 104 mg (0.33 mmol) of 17 are dissolved
in 3.83 mL of anhydrous CH2Cl2 and the solution is cooled to -20 °C. 0.99 mL of
BBr3 are added in the flask. The mixture is stirred at -20 °C for 5 min. Then the
flask is heated at 0°C and left in this condition for 1h.
After that the mixture is cooled at RT, the reaction is quenched with water
and the treatment proceeds with the extraction with AcOEt; the organic phase is
washed with brine, dried, filtrated and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 8:2).  75.9 mg (0.255 mmol)  of the product  are  obtained.  The
yield of the yield 76 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.69 (s, 3H), 5.68 (exchangeable, s, 1H); 6.89 (d, 1H, J= 8.3 Hz); 7.10 (d,
1H, J= 8.4 Hz); 7.31 (dd, 1H, J= 8.4 Hz, J= 2.1 Hz); 7.46 (d, 1H, J= 2.1 Hz); 7.70
(d, 1H, J= 8.3 Hz); 13.08 (exchangeable, s, 1H).
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Compound 9f
A solution of  16d (77 mg, 0.26 mmol) in EtOH (5 mL) is treated with an
aqueous solution of NH2OH·HCl (1.2 mL, 0.52 mmol). The mixture is heated at
50 °C and it is stirred at this temperature for 48h. After this period, the mixture is
cooled to RT, EtOH is evaporated and the resulting phase is diluted with water;
then,  it  is  extracted with AcOEt and washed with brine.  The organic phase is
dried, filtrated and concentrated.
The crude product  is  purified with a  flash chromatography on silica  gel
(CH2Cl2:MeOH= 99:1→98:2). 62.9 mg (0.201 mmol) of the product are obtained.
The yield of the reaction is 77 %.
1H NMR (400 MHz, acetone-d6), δ (ppm):
2.41 (s, 3H); 6.94 (d, 1H, J= 8.2 Hz); 7.10 (d, 1H, J= 8.4 Hz); 7.28 (dd, 1H,
J= 8.4 Hz,  J= 2.2 Hz);7.45 (d, 1H,  J= 2.0 Hz); 7.57 (d, 1H,  J= 8.3 Hz); 9.02
(exchangeable,  bs,  1H);  10.98 (exchangeable,  bs,  1H); 12.44 (exchangeable,  s,
1H).
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Compound 44
In a flame-dried two-necked flask 8.23 g (36.6 mmol) of N-iodosuccinimide
are dissolved into a concentrated solution of H2SO4 (22 mL) at 0 °C under argon
atmosphere; the resulting solution is maintained under agitation at 0 °C for 40
min. 
Separately,  5.00  g  (24.4  mmol)  of  2-methyl-1-nitro-3-
(trifluoromethyl)benzene are dissolved into 15 mL of concentrated H2SO4. This
latter solution is dropped to the former and the resulting mixture is stirred at 5 °C
for 5 h; then, it is heated to RT and stirred for 16 h.
After this period, the reaction is quenched with water ice and it is extracted
with AcOEt, washed with sodium thiosulfate to remove the excess of I2 and finally
washed  with  brine.  The  organic  phase  is  dried  over  Na2SO4,  filtrated  and
concentrated. Because of the presence of succinimide in the crude product, hexane
is  added  to  the  mixture:  since  only  44  is  soluble  in  the  organic  solvent,  the
suspension is filtrated under vacuum with a bell jar and the filtrate is concentrated.
The aspect of the purified product is a yellow solid. The amount of the product is 
7.59 g (22.9 mmol).
The yield of this reaction is 94 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.50 (q, 3H, 5JH-F= 1.5 Hz); 8.15 (m, 1H); 8.20 (d, 1H, Jmeta = 1.7 Hz).
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Compound 45
In a vial 59.4 mg (0.226 mmol) of PPh3 are dissolved in EtOH (3.4 mL) and
dry toluene (3.4 mL) under argon atmosphere and then 10.2 mg (0.045 mmol) of
Pd(OAc)2 are added to the solution. The mixture is stirred under argon for 10 min.
After this time 500 mg (1.51 mmol) of 44, 3.4 mL of a 2 M Na2CO3(aq) and
295 mg (2.41 mmol) of phenylboronic acid are added in sequence. The mixture is
heated to 100 °C and the mixture is stirred for 24 h.
The procedure is repeated for eight vials.
After this period, the reaction is quenched with water; then the mixtures of
the eight vials are gathered and the final mixture is extracted with AcOEt and
washed with brine. The crude product is dried over Na2SO4 and concentrated.
The crude product is purified by flash chromatography (n-hexane:AcOEt=
99:1) on silica gel to obtain the 3.04 g (10.8 mmol) of the product as a yellow
solid.
The yield of the reaction is 89 %.
1H NMR (400 MHz, CDCl3) δ (ppm):
2.60 (d, 3H, 5JH---F = 1.4 Hz); 7.43-7.53 (m, 3H); 7.58- 7.61 (m, 2H); 8.07 (s,
1H); 8.1 (d, 3H, Jmeta = 1.7 Hz).
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Compound 46
In a flame-dried two-necked flask 2.4 g (21 mmol) of tBuOK are dispersed
in  34 mL of  anhydrous Et2O at  0  °C.  34 mL of  dry MeOH are  added and a
complete dissolution is obtained. Then, 2.3 g (21 mmol) of dimethyl oxalate are
added to the solution and the mixture is stirred for 10 min at 0 °C.
Separately, 2.95 g (10.5 mmol) of 45 are dissolved in 13 mL of dry Et2O in a
flask and the resulting solution is slowly added to the former at 0 °C. Then, the
mixture is heated at RT and stirred for 15h. After this period, the flask is cooled at
0  °C  and  the  reaction  is  quenched  with  water  ice;  then  the  mixture  pH  is
neutralized with 1 N aqueous HCl.
The treatment consists in the extraction with AcOEt, washing with brine and
drying over Na2SO4. The crude product is  concentrated and purified by flash
chromatography on silica gel 
(n-hexane:AcOEt= 9:1→ 8:2). Two fractions A and B are gathered. 
The yield of the reaction is calculated considering the 2.33 g (6.34 mmol) of
the pure fraction A and it is 77 %. 
1H NMR (400 MHz, CDCl3), δ (ppm):
3.97 (s, 3H); 4.71 (s, 2H); 7.50-7.56 (m, 3H); 7.62-7.65 (m, 2H); 8.20 (d,
1H, Jmeta= 1.8 Hz); 8.44 (d, 1H, Jmeta= 1.9 Hz).
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Signals imputable to the enolic form (~ 16%): 3.98 (s, 3H); 6.19 (enolic
form, d, 1H,  J= 1.7 Hz); 6.81 (enolic form, m, 1H); 8.12 (enolic form, d, 1H,
Jmeta= 1.8 Hz); 8.23 (enolic form, d, 1H, Jmeta= 1.9 Hz).
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Compound 41
In  a  flame-dried  two-necked  flask,  850  mg  (4.48  mmol)  of  SnCl2 are
dissolved in 1.80 mL of dry DME. Some molecular sieves are added in the flask;
then, the temperature is reduced to 0 °C.
Separately, 660 mg (1.79 mmol) of 46 are dissolved in 1.60 mL of dry DME
and the resulting solution is slowly added to the previous mixture. The bath is
removed and the mixture is stirred at RT overnight covering the flask with an
aluminum foil.
After this period, the mixture is filtrated to remove the molecular sieves and
then it is directly concentrated.
The  purification  is  done  with  a  flash  chromatography  on  silica  gel  (n-
hexane: AcOEt= 85:15) and 320 mg (0.95 mmol) of the product are obtained as a
yellow solid.
The yield of the reaction is 53 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
4.04 (s, 3H); 7.21 (dd, 1H, J= 1.5 Hz, 5J= 0.9 Hz); 7.39-7.42 (m, 1H); 7.47-
7.51 (m, 2H); 7.67-7.71 (m, 3H); 7.92 (s, 1H); 10.49 (s, 1H).
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Compound 47
In a flame-dried two-necked flask 780 mg (2.32 mmol) of 41 are dissolved
in 16.5 mL of HPLC acetone; then, in series, 1.92 g (4.64 mmol) of K2CO3 and
1.91 g (4.64 mmol) of acetobromo-α-D-glucose are added to the solution. A color
change from orange to yellow is observed. The flask is covered with aluminum
foil.
The solvent is evaporated and the resulting mixture is washed with water
and  then,  with  brine.  The  crude  product  is  dried  over  Na2SO4 and  then  it  is
filtrated. The crude product is concentrated under vacuum to obtain a dry yellow
solid.
The purification consists in the addiction of a little bit of tepid AcOEt to the
solid to obtain a solution; this is filtrated in a flask and some n-hexane is slowly
added to the gathered filtrate until a clouding of the solution is noted. Then, the
flask is covered with aluminum foil and it is left overnight. After this time, a little
bit of very small crystals are observed on the flask bottom, so the mixture is left in
the  previous  condition  overnight  again;  at  this  point,  the  crystallization  is
happened and the mixture is filtrated with a bell jar to gather the solid using  n-
hexane to wet the flask. A first fraction of the precipitate is obtained.
The  filtrate  is  undergone  to  the  same  way  of  purification;  after  the
requirement time, a second fraction of the precipitate is gathered.  Also in this
case, the filtrate is used to do another possible purification in the same condition
but none crystallization has been noted.
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The analysis of 1H NMR spectrum of both the product fractions reveals that
they are made of the purified product.
The total amount of the product is 978 mg (1.47 mmol).
The yield of the reaction is calculated considering both the precipitates and
it is 63 %.
1H NMR (400 MHz, MeOD), δ (ppm):
1.75 (s, 3H); 2.03 (s, 3H); 2.05 (s, 3H); 2.19 (s, 3H); 3.75 (ddd, 1H, J= 10
Hz, J= 7.8 Hz, J= 2.2 Hz); 3.93 (s, 3H); 3.96 (dd, 1H, 2JAB= 12.5 Hz, J= 2.4 Hz);
4.3 (dd, 1H, 2JAB=12.4 Hz, J= 4.4 Hz); 5.24 (dd, 1H, J= 10.0 Hz, J= 9.2 Hz); 5.36-
5.46(m, 2H); 5.60 (d, 1H, J= 8.0 Hz); 7.30 (dd, 1H, J= 2.7 Hz, J= 1.8 Hz); 7.37-
7.41 (m, 1H); 7.45-7.49 (m, 2H); 7.62-7.64 (m, 2H); 7.72 (dd, 1H, J= 1.5 Hz, J=
0.8 Hz); 8.09 (m, 1H).
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Compound 43
In a flame-dried two-necked flask 424 mg (0.64 mmol) of 47 are dissolved
in 12.8 mL of HPLC MeOH and the resulting solution is cooled to 0 °C. 0.2 mL of
25 % MeONa/MeOH is added and the mixture is  stirred at  RT for 19 h.  The
treatment consist in the addiction of cleaned amberlyst under agitation until pH
neutralization; then,  the mixture is filtrated and the filtrate is concentrated and
dried.  The  crude  product  is  purified  with  flash  chromatography  on  silica  gel
(CHCl3:MeOH= 9:1). 255 mg (0.51 mmol) of the product are obtained. The aspect
of the product is a white solid. 
The yield of the reaction is 80 %.
1H NMR (400 MHz, MeOD), δ (ppm);
3.49-3.63(m, 3H); 3.74-3.83 (m, 2H); 3.98-3.99(s, 3H); 5.22 (d, 1H, J= 8.0
Hz); 7.23 (m,  1H); 7.38-7.42(m, 1H); 7.48-7.52(m, 2H); 7.76-7.79(m, 3H); 8.33
(s, 1H).
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Compound 49
In a vial 89.3 mg (0.34 mmol) of PPh3 are dissolved in EtOH (4.50 mL) and
dry toluene  (4.50  mL)  under  argon atmosphere.  Successively 15.3  mg  (0.068
mmol)  of  Pd(OAc)2 are  added  to  the solution.  The  mixture  is  maintained  in
agitation under argon for 10 min.
Then 500 mg (2.27 mmol) of 4-bromo-1-fluoro-2-nitrobezene, 4.50 mL of 2
M  Na2CO3(aq) and  360  mg  (2.95  mmol)  of  phenylboronic  acid  are  added  in
sequence to the previous solution. The mixture is heated to 100 °C and left for 24
h.
The mixture is then cooled to RT and the reaction is quenched with water. It
is then extracted with AcOEt and washed with brine. The crude product is dried
over Na2SO4 and concentrated.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 99:1) to 564 mg (2.60 mmol) of the product as a yellow solid. 
The yield of the reaction is > 99 %.
1H NMR (400 MHz, CDCl3) δ (ppm):
7.37 (dd, 1H,  3JH---F=10.5 Hz,  Jorto=8.7 Hz);7.41-7.45 (m, 1H);7.47-7.51(m,
2H); 7.55-7.58 (m, 2H); 7.84 (ddd,1H, Jorto= 8.6 Hz, 4JH---F= 4.2 Hz, Jmeta= 2.4 Hz);
8.27 (dd, 1H, 4JH---F= 7.0 Hz, J meta= 2.4 Hz).
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Compound 50
In a flame-dried two-necked flask 1.61 g (7.41 mmol) of 49 are dissolved in
8.50 mL of dry MeOH. Then 1.24 g (14.8 mmol) of NaHCO3 and 930 mg (7.41
mmol) of methyl glycinate hydrochloride are added in sequence to the solution.
The mixture is heated to 80 °C in an oil-bath with an air-refrigerant and it is
left  in  this  condition  overnight.  When  the  temperature  reaches  80  °C a  color
change from yellow to orange is observed.
When the mixture reaches the RT it is treated. The treatment starts with the
evaporation of the MeOH; after this water is added to the solid mixture and the pH
is neutralized with 1 N aqueous HCl. At this point the mixture is extracted with
AcOEt  and  washed  with  brine;  finally  it  is  dried  over  Na2SO4,  filtrated  and
concentrated under vacuum.
The crude product is purified with flash chromatography on silica gel (n-
hexane:AcOEt= 85:15→ 8:2→ 7:3).  805  mg  (2.81  mmol)  of  the  product  are
obtained as an orange solid.
The yield of the reaction is 40 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
3.85 (s, 3H); 4.17 (d, 2H, J= 5.2 Hz); 6.79 (d, 1H, Jorto= 8.8 Hz); 7.32-7.36
(m, 1H); 7.42-7.46 (m, 2H); 7.54-7.57 (m, 2H); 7.75 (dd, 1H, Jorto= 8.8 Hz, Jmeta=
2.3 Hz); 8.43 (bt, 1H, J= 2Hz); 8.48 (d, 1H, Jmeta= 2.2 Hz).
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Compound 51
In a  flame-dried  two-necked flask,  204 mg (3.78 mmol)  of  MeONa are
dissolved in 16.8 mL of dry MeOH. In another flame-dried two-necked flask 400
mg  (1.40  mmol)  of  50  are  introduced; after  that  8.40  mL of  MeONa/MeOH
solution are added to the starter material. The flask with the reaction mixture is
covered with an aluminum foil.
After 2 h, a sample is taken for a TLC and the absence of starter material
traces  is  observed.  Successively,  the  mixture  is  treated:  at  first,  MeOH  is
evaporated  and the  solid  mixture  is  recovered  with  water  and Et2O; then,  the
aqueous phase is neutralized with AcOH and it is extracted with  Et2O, washed
with brine and dried over Na2SO4. The crude product is filtrated and concentrated.
It is then purified with a flash chromatography on silica gel (n-hexane: AcOEt=
3:7) to obtain a yellow solid.
During the previous extractions,  a precipitate takes place in the interface
between the two phases and it results insoluble both in the aqueous phase and in
the organic phase. So the precipitate is gathered in the aqueous phase and it is
extracted with Et2O twice; because of the insolubility of the precipitate in Et2O an
extraction with AcOEt is done and it is observed that the precipitate is weakly
soluble in the last solvent. The organic phase is dried, filtrated and concentrated.
The undissolved sizable amount of precipitate present in the aqueous phase
is filtrated under void with a bell jar.
The NMR spectrum of the precipitate shows that the insoluble compound
corresponds to the product.
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The total amount of the product is 112 mg (0.42 mmol).
The yield of the reaction is 30 %.
1H NMR product purified with column (400 MHz, MeOD), δ (ppm):
4.88 (s, 3H); 7.36-7.39 (m, 1H); 7.46-7.5 (m, 2H); 7.67-7.71 (m, 3H); 7.78
(d, 1H, Jorto= 8.9 Hz); 7.82 (d, 1H, Jmeta= 0.8 Hz).
1H NMR precipitate sample (400 MHz, MeOD), δ (ppm):
4.11 (s, 3H); 7.36-7.40 (m, 1H); 7.46-7.50 (m, 2H); 7.66-7.70 (m, 3H); 7.78
(d, 1H, Jorto= 8.9 Hz); 7.81 (d, 1H, Jmeta= 0.8 Hz).
1H NMR precipitate sample (400 MHz, DMSO-d6), δ (ppm).
3.94 (s, 3H); 7.37-7.41 (m, 1H); 7.47-7.51 (m, 2H); 7.65 (dd, 1H, Jorto= 8.6
Hz,  Jmeta=  1.8  Hz);  7.72-7.75  (m,  3H);  7.81  (d,  1H,  Jorto=  8.6  Hz);  12.49
(exchangeable, bs, 1H).
13C NMR purified product (400 MHz, MeOD), δ (ppm):
53.26; 109.31; 121.53; 125.49; 125.49; 128.43 (3C); 128.7; 130.03 (3C);
134.99; 140.82; 142.10; 159.50.
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Compound 48
40 mg (0.15 mmol) of  51  are dissolved in 1.5 mL of a THF/MeOH (1:1)
mixture. After this 0.45 mL of a 2 M LiOH(aq) are added to the solution.
After 17 h, a sample is taken and it emerges that there aren’t traces of the
starter material  so the mixture can be treated.  At first,  the organic solvent are
evaporated and the mixture is washed with Et2O to obtain a limpid yellow organic
phase; the organic phase is washed with brine, dried with Na2SO4, filtrated and
concentrated.
The aqueous phase is neutralized using 1 N aqueous HCl and extracted with
AcOEt; during the extractions a precipitate takes place in the interface between
the  two phases  and it  results  insoluble both  in  the  aqueous  phase  and  in  the
organic  phase.  For  this  reason  the  first  phase  is  extracted  several  times  with
AcOEt  until  it  results  limpid  and all  the  precipitate  is  obtained.  The resulting
organic phase appears cloudy. Io order to dissolve the suspended solid, a small
volume of MeOH is added to the organic phase; after this the crude product is
dried over Na2SO4, filtrated and concentrated. 24.1 mg (0.09 mmol) of the product
are obtained as a white solid.
The yield of the reaction is 73 %.
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1H NMR (400 MHz, DMSO-d6), δ (ppm):
7.34-7.39 (m, 1H); 7.46-7.51 (m, 2H); 7.53 (dd, 1H, Jorto= 8.4 Hz, Jmeta=1.8
Hz); 7.69-7.73 (m,
4H); 8.50 (s, 1H); 12.18 (exchangeable, bs, 1H).
1H NMR (400 MHz, DMSO-d6/D2O), δ (ppm):
7.34-7.38 (m, 1H); 7.46-7.56 (m, 3H); 7.70-7.74 (m, 4H); 8.44 (s, 1H).
1H NMR (400 MHz, DMSO-d6/D2O after 1h), δ (ppm):
7.34-7.38 (m, 1H); 7.46-7.56 (m, 3H); 7.70-7.74 (m, 4H); 8.44 (s, 1H).
13C NMR (400 MHz, DMSO-d6), δ (ppm):
106.96; 119.82; 121.18; 126.99 (2C); 128.97 (3C); 131.90; 135.36; 138.19;
140.23; 140.62
The signal relative to the carboxylic carbon atom apparently is not visible.
DEPT-135 (400 MHz, DMSO-d6), δ (ppm):
40.01; 40.22; 107.43; 120.28; 121.65; 127.47; 127.60; 129.44; 140.71.
No CH2 signals are detected.
HSQC: with the exception of proton signal at  12.18 ppm, all  the proton
signals of the 1H NMR spectrum in DMSO-d6 are related with 13C NMR signals.
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Compound 58
In a flame-dried two-necked flask, 500 mg (3.18 mmol) of 5-nitrothiophene-
2-carbaldehyde are dissolved in 22 mL of anhydrous CH2Cl2. After this, 0.7 mL
(10 mmol) of BAPN are added to the solution. Few minutes later a color change
from yellow to purple is observed. The mixture is left to react overnight.
After this time frame, the reaction mixture is transferred in a one-necked
flask and it is concentrated under vacuum.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.81 (t, 2H, 3J= 6.5 Hz); 3.86 (td, 2H, 3J= 6.6 Hz, 4J= 1.4 Hz); 7.28 (d, 1H,
3J= 4.2 Hz); 7.88 (d, 1H, 3J= 4.0 Hz); 8.41 (m, 1H).
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Compound 59
The reaction mixture obtained in the first step is transferred in a flame-dried
two-necked flask. The mixture is dissolved in 22.2 mL of anhydrous MeOH and
the flask is cooled at -20 °C using a bath with water ice and NaCl. After this,
under argon, 890.2 mg (23.53 mmol) of NaBH4 are slowly added to the mixture;
the temperature is maintained at -20 °C until the end of the effervescence that
takes place. After 30 min a color change from red to purple is observed. Then, the
mixture is left at RT for 3h.
After this period of time, the reaction is quenched with water at 0 °C. When
the temperature reaches the RT, the mixture is extracted with AcOEt several times
due to the coloration of the two phases and the subsequent difficulty to identify
the interface. The organic phase is finally washed with brine, dried over Na2SO4,
filtrated and concentrated.
The TLC realized with a sample of crude product shows that it consists in a
mixture of the starter imine and the product.
The  mixture  is  separated  and  the  product  is  purified  with  flash
chromatography on silica gel (n-hexane:AcOEt= 6:4→ 1:1) and finally 126 mg
(0.60 mmol) of the product are obtained as a red oily liquid. The starter imine is
gathered too. 
The yield of the reaction is 19 %.
1H NMR (400 MHz, CDCl3), δ (ppm):
2.57 (t, 2H, 3J= 6.5 Hz); 3.00(t, 2H, 3J= 6.5 Hz); 4.06 (d, 2H, 4J= 0.9 Hz);
6.91 (dt, 1H, 3J= 4.2 Hz, 4J= 1.0 Hz); 7.81 (d, 1H, 3J= 4.1 Hz).
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Compound 57
126 mg (0.60 mmol) of 59 are dissolved in 3.00 mL of dry MeOH in a flask
under argon. A solution of Et2O·HCl is dropped in the same flask until a blue
precipitate starts to shape and a color change from red to yellow is observed. In
this case 0.5 mL of Et2O·HCl have been used.
The purification consists in the filtration of the solution under void with a
bell jar. The precipitate is then washed with Et2O and a blue solid is obtained.
After the first filtration, the yellow filtrate is characterized by the presence
of  a  white  solid; for  this  reason the  mixture  is  filtrated  again  with  the  same
procedure. The white precipitate is gathered.
The  1H NMR spectra of both solids reveal that they are constituted of the
purified product. The reaction yield is 67 % and it is calculated considering the
amounts of both the precipitates that is 100 mg (0.41 mmol).
1H NMR first precipitate (400 MHz, D2O), δ (ppm):
3.01 (t, 2H, J= 6.8 Hz); 3.50 (t, 2H, J= 6.8 Hz); 4.57 (s, 2H); 7.32 (d, 1H, J=
4.2 Hz); 8.00 (d, 1H, J= 4.2 Hz).
1H NMR second precipitate (400 MHz, D2O), δ (ppm):
3.03-3.06 (t, 2H); 3.51-3.54 (t, 2H); 4.6 (s, 2H); 7.35-7.36 (d, 1H); 8.03-8.04
(d, 1H).
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13C NMR (400 MHz, D2O), δ (ppm):
14.88; 42.44; 45.26; 117.34; 129.82; 130.92; 139.22; 152.67.
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